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SUMMARY 
 
It has always been a major challenge to ensure that drugs possessing a narrow absorption window 
are delivered in such a way as to ensure that plasma concentrations are within the therapeutic window 
while maintaining good patient compliance. This is due to the inherent low bioavailability caused by 
the narrow site of absorption, which is usually located in the upper parts of the small intestines. The 
logical solution to this problem is to increase the duration in which the drug is held within the stomach. 
Many mechanisms have been investigated in order to achieve this, some more successful than 
others. 
 
This study sought to develop two novel dual mechanism gastroretentive drug delivery systems which 
will deliver the model drugs, metformin and ciprofloxacin, in a zero order fashion over a period of 12 
hours. In so doing, the drug plasma concentrations will be maintained within the therapeutic window, 
thus preventing side-effects commonly associated with the peaks and troughs in plasma 
concentrations. The mechanisms of buoyancy and gastroadhesion were employed in order to achieve 
gastroretention. 
 
Polymers were selected due to their individual characteristics and include poly-lactic-co-glycolic acid 
(PLGA), polyacrylic acid (PAA), alginate and pectin and the model drug employed was metformin 
hydrochloride. Fifteen formulations were obtained using the design of experiments Box-Behnken 
approach, all of which displayed excellent buoyancy. The yield was found to be above 80% in all 
cases, although due to the high water solubility of metformin, drug entrapment efficacy was only 
between 18 and 54%. Mean dissolution time (MDT12) and gastroadhesive strength were used as the 
formulation responses in order to optimize the formulation. Furthermore, the molecular mechanics 
force field simulations were performed to corroborate the experimental findings. Drug release profiles 
revealed three different release kinetics, namely burst; first-order and zero-order release. Varying 
gastroadhesive results were obtained, and were highly sensitive to changes in polymer 
concentrations. Physicochemical characterisation of the gastrospheres was conducted on the 
optimized formulation, including Fourier Transform Infrared spectroscopy (FTIR), surface area and 
porosity analysis and Scanning Electron Microscopy (SEM). The spatial disposition and energetic 
profile of the sterically constrained and geometrically optimized multi-polymeric complex of alginate, 
pectin, PAA and PLGA corroborated the experimental results in terms of in vitro drug release and 
gastroadhesive strength of the fabricated gastrospheres. 
 
A novel microparticle formulation was developed which was loaded within a pre-developed 
gastrosphere design which is both gastrofloatable and gastroadhesive. A combination of chitosan and 
polymethacrylate were used in order to form the ioniclly crosslinked microparticles. A face-centered 
central composite design was constructed for this study which resulted in 14 statistically derived 
formulations. In order to identify the optimal polymeric concentrations, microparticle drug entrapment, 
microparticle yield and mean dissolution time (MDT12) were utilized as formulation constraints. 
Physicochemical and morphological characterisation was conducted on the optimized formulation, 
including Fourier Transition Infrared (FTIR) spectroscopy and Scanning Electron Microscopy (SEM) 
characterisation. Regression analysis and constraint optimization was utilized in order to obtain the 
optimal formulation. Surface response analysis was utilised in order to determine the interactions 
between chitosan and Eudragit®. Microparticle yield was relatively high, ranging from 77 to 92%, while 
drug entrapment ranged between 50 to 73%. Drug release profiles displayed an initial burst release 
followed by zero order release over a 12 hour period. To mechanistically elucidate the complexation 
and crosslinking mechanism of Eudragit® and sodium tripolyphosphate with respect to chitosan, we 
employed computer-aided modelling of the three-dimensional structure of the active residues of the 
guest molecules with the respective substrate, to predict the possible orientation of residues most 
likely affecting the drug delivery system’s performance. 
 
The in vivo release of ciprofloxacin and metformin was investigated through UPLC analysis of plasma 
samples obtained from white pigs following the administration of the drug delivery systems. The 
release of each system was compared to the release of a product currently on the market containing 
the same drug. Drug release from both delivery systems was superior to that of products currently 
available in South Africa, displaying a more controlled rate of release.  
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CHAPTER 1 
Background, Rationale and Motivation for this Study 
 
1.1. INTRODUCTION 
The time taken for a drug delivery system to pass through the stomach remains fairly 
constant at three hours, while the transit time through the small and large intestines 
may extend to over twenty hours (Davis, 2005). The gastric time will determine the 
duration that drug remains in contact with its specific site of absorption (Davis, 2005). 
The efficacy of drug therapy may therefore be enhanced by prolonging transit time of a 
drug through the gastrointestinal tract (Tang et al., 2007). 
 
Drugs which have a poor bioavailability or a narrow absorption window are ideal 
candidates for incorporation into gastroretentive prolonged release drug delivery 
systems (Streubel et al., 2006). Examples of such drugs include acyclovir (23%), 
captopril (65%), riboflavin (15%), metformin (50%) levodopa (30%), nitrofurantoin 
(40%) and ciprofloxacin (69%) (El-Gibaly, 2002; Davis, 2005; Fukuda et al., 2006; 
Ahmed and Ayres, 2007). 
 
Prolonging the release of drugs within the gastrointestinal tract by way of increasing 
gastric residence time offers numerous advantages over conventional oral immediate-
release drug delivery systems (Chavanpatil et al., 2006; Streubel et al., 2006; Tang et 
al., 2007). Advantages that are more specific to prolonged release, due to the 
enhanced gastric residence time, are that the drug is released into the stomach and 
intestines over a longer period of time, allowing an increase in time available for drugs 
with low bioavailability or narrow absorption windows to be absorbed without flooding 
their specific site of absorptions. 
 
There are numerous factors which affect gastric emptying and as a result may 
influence the gastric retention time of an oral drug delivery system. The size and shape 
of the system affects its transit through the pyloric sphincter, while the density will 
determine whether the system would float on the gastric contents or sink to the base of 
the stomach. These factors are important to consider when designing a gastroretentive 
drug delivery system. Biological factors also play an important role in the functioning of 
the gastrointestinal tract and include the age and gender of the patient, the presence 
of disease, as well as the patients level of physical activity, body mass index and 
posture. Further factors that influence gastric emptying include the ingestion of food 
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and particular drugs which may have an impact on gastrointestinal motility (Fukuda et 
al., 2006; Streubel et al., 2006). 
 
In addition to systemic treatment, this multi-unit drug delivery system may also be 
applied to the local treatment of conditions affecting the stomach itself, including 
nausea, vomiting and gastric ulcers. Referring specifically to domperidone, a potent 
peripheral dopamine antagonist, is commonly indicated for the treatment of nausea, 
vomiting and dyspepsia. It may be a suitable drug model to be incorporated within a 
gastroretentive drug delivery device, offering an increase in its duration of action.  
 
Various approaches have been investigated in order to retain a drug delivery system in 
the stomach for an extended period of time. These approaches include swelling and 
expanding systems, floating systems and the use of a bioadhesive system (El-Gibaly, 
2002). Of late, bioadhesive polymers have received much attention as absorption 
enhancers, allowing the drug delivery system to be anchored at a specific site, 
ensuring maximum absorption of the drug (Tur and Ch’ng, 1998). 
 
The major drawback of a gastroadhesive drug delivery system is that of mucosal 
shedding, where mucosal cells of the stomach are regularly sloughed off and replaced 
in order to retain the integrity of the mucosal lining, which may reduce the adherence 
of the polymeric system. Furthermore, there is the possibility of the delivery system to 
adhere to other mucosal linings such as that of the oesophagus (Streubel et al., 2006). 
These failings may be overcome by the incorporation of the drug within multiple units.  
 
A gastric retentive prolonged-release drug delivery system can be developed either as 
a single or multiple-unit formulation. The major disadvantage of a single-unit 
formulation is their ‘all-or-nothing’ emptying process, which could lead to gastric 
irritation and a high variability in bioavailability (El-Gibaly, 2002). However, multi-unit 
drug delivery systems offer more reproducible gastric residence times, reduced 
absorption variability between subjects and offers a superior dispersion pattern 
through the gastrointestinal tract, resulting in a reduced risk of damage to the local 
mucosa (Goole et al., 2007). Mucoadhesive drug delivery systems have not yet 
reached their full potential to deliver drugs within the gastro-intestinal tract due to the 
failure to achieve sufficiently prolonged controlled release of drugs (Bernkop-
Schnürch, 2005). 
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In this study, the proposed drug delivery system for increasing gastric retention time 
will be designed and formulated in such a manner as to overcome the above 
mentioned limitations. Therefore, in order to further increase the gastric residence time 
of the drug delivery system, it may be advantageous to make use of more than one 
gastroretentive mechanism when formulating the delivery system. In this study, a 
multi-unit approach will be taken that will possess both gastrofloatable and 
gastroadhesive properties. In so doing, the drug delivery system would initially be 
buoyant on the surface of gastric contents, and as the gastric contents move into the 
intestine, the multi-units would adhere to the mucosal surface of the stomach, 
extending the length of time in which the drug delivery system is retained within the 
stomach. Further, by utilising a multi-unit approach has the added benefit that it will 
overcome the disadvantages caused by sloughing of the gastric mucosa. 
 
1.2. RATIONALE AND MOTIVATION 
Through the utilisation of a double gastrofloatable and gastroadhesive approach 
incorporated into a multi-unit drug delivery system, numerous limitations with 
conventional gastrofloatable and gastroadhesive drug delivery systems may be 
overcome.  Due to the buoyancy of the drug delivery system there may be a desirable 
portion that would remain suspended within the gastric contents and later have the 
ability to adhere to the mucosal lining. This will provide a solution to overcome the 
difficulties brought about due to mucosal shedding. The use of the multi-unit system 
will also ensure that there is no risk of all-or-none drug release. 
 
In order to deliver the multi-units, polymeric spheres will be incorporated into a 
capsule. On contact with gastric fluid, the capsule, which is in itself buoyant, will float 
on the surface of the stomach contents. After the capsule has become hydrated and 
dissolves, the polymeric spheres will be released. The polymeric spheres will hydrate 
and swell, enabling them to remain buoyant. Buoyancy of the spheres would also be 
improved as a result of lyophilization. Lyophilization of spheres results in a highly 
porous structure, which ultimately results in a reduced density, allowing it to remain 
buoyant within the stomach contents. The spheres will be able to adhere to the 
mucosal lining of the stomach due to the adhesive characteristics of the polymers.  
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Figure 1.1: Schematic of the proposed mechanism of drug release from the 
gastrofloatable and gastroadhesive drug delivery system. 
 
1.3. AIM AND OBJECTIVES OF THIS STUDY 
The aim of the present study is to develop an oral drug delivery system which will 
enhance the bioavailability of drugs which are normally associated with a narrow 
absorption window. Commercially available dosage forms are synonymous with 
repeated high doses of the drug in order to obtain the required therapeutic plasma 
concentrations. This, however, results in side effects which may inhibit patient 
compliance. Drug delivery systems which are currently on the market are costly and 
the method of controlled release may easily be destroyed by uninformed patients i.e. 
by breaking or crushing of tablets. 
 
To achieve the aforementioned aim, the following objectives are highlighted: 
1. To review the diverse novel systems developed for the improved delivery of 
narrow absorption window and low bioavailability drugs to the patient in order 
to enhance therapeutic outcomes and improve patient compliance. 
2. To identify a single feasible method for the formulation of a gastroretentive 
gastrosphere and microparticulate system. 
Gastroadhesive 
Swollen 
gastrospheres 
Gastrofloatable 
Capsule system 
containing lyophilised 
polyspheres 
Drug 
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3. To experimentally synthesise several variants of the preferred gastrosphere 
and microparticulate system employing a Box-Behnken Response Surface 
Design or Face-Centered Central Composite Design to elucidate the effect of 
independent variables; the upper and lower limits of which were set during 
preliminary investigations. This will facilitate a mechanistic evaluation of 
possible correlations between independent variables. 
4. To determine the optimum parameters to synthesise an ideal polymeric 
gastrosphere and multiparticulate system based on statistical optimisation 
implemented via the Response Surface Methodology. 
5. To assess the in vivo drug release characteristics of the optimum gastrosphere 
and multiparticulate system.  
 
1.4. POTENTIAL BENEFITS OF STUDY 
i. The development of a multi-unit gastrofloatable and gastroadhesive drug delivery 
system, intended for the delivery of drugs possessing a narrow absorption window 
and low bioavailability. 
ii. Present research findings related to the developed technology at national and 
international conferences as well as publication in international scientific peer-
reviewed journals. 
iii. Attract interest in the developed technology from pharmaceutical industry. 
iv. The application for a patent on the developed technology. 
 
1.5. OVERVIEW OF THE DISSERTATION 
The dissertation was constructed as follows for attainment of the aforementioned aims:  
 
Chapter 1 of this study contains an introduction into the topic of gastric retentive drug 
delivery systems, the rationale for the research and aim and objectives.  
 
Chapter 2 concisely provides a descriptive review of the current global situation of 
research into gastroretentive drug delivery systems. This section elaborates on the 
factors that need to be taken into account and the different methods utilised in order to 
attain gastric retention and recent innovations are described. 
 
Chapter 3 of this study describes the development, design and optimisation of the 
gastrosphere drug delivery system. A candidate formulation, possessing the 
advantages of simple and effective manufacture, and favourable in vitro release 
behaviour and mucoadhesion, was identified utilising a model-independent approach 
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for further investigation and optimisation. A Box-Behnken experimental design was 
employed to synthesise several variants of the candidate formulation, which were 
characterised in terms of their mucoadhesion and drug release properties. The 
optimum gastrosphere system, having appropriate mucoadhesion and drug release 
characteristics, was identified by instituting the principles of Response Surface 
Methodology. 
 
Chapter 4 focuses on the development of a novel microparticle formulation loaded 
within gastrospheres developed in Chapter 3. A Face-Centered Central Composite 
Design was constructed which resulted in 14 statistically derived formulations. In order 
to identify the optimal polymeric concentrations, microparticle drug entrapment, 
microparticle yield and mean dissolution time (MDT12) were utilized as formulation 
constraints. Regression analysis and constraint optimization was utilized in order to 
obtain the optimal formulation.  
 
Chapter 5 discusses the in vivo animal testing and UPLC analysis of metformin and 
ciprofloxacin loaded within the gastrosphere and microparticle loaded drug delivery 
systems respectively and comparisons are made between these two delivery systems 
and products currently available on the South African market. 
 
Chapter 6 concludes the dissertation and ties together the significant issues 
addressed regarding the formulation of a gastroretentive drug delivery system, with 
recommendations for future investigations. 
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CHAPTER 2 
Gastroretentive Drug Delivery Systems: Current Developments in Novel System 
Design and Evaluation 
 
2.1.  INTRODUCTION  
Oral drug delivery has become the mainstay of treatment due to higher patient 
compliance and reduced patient discomfort. However, there are still many drugs 
demonstrating poor efficacy and low bioavailability via this route. These drugs include 
those which a) act locally within the stomach such as amoxicillin (Whitehead et al., 
2000), b) are absorbed within the stomach or specific parts of the upper intestines 
such as furosemide (Sakkinen et al., 2002), c) are unstable in intestinal fluids such as 
captopril (Seta et al., 1988) and d) are poorly soluble within the alkaline environment of 
the intestines such as diazepam (Wurster et al., 2003).  
 
The most important factor leading to the low bioavailability of many drugs is due to 
their narrow absorption window (NAW), most commonly situated in the upper part of 
the small intestines, namely the duodenum and jejunum. These segments contain 
extensive absorption properties although, due to the rapid transport past the sites, 
absorption is limited (Hoffman et al., 2004). It is therefore evident that by extending the 
time that a drug is in contact with its specific site of absorption, the greater the amount 
of drug that may be absorbed. This can be achieved through the design of a drug 
delivery system which is retained within the stomach.  
 
Through the use of a gastroretentive drug delivery system, the delivery system is 
retained within the stomach by either one or a combination of mechanisms, allowing 
the drug to go into solution within the stomach, pass through the pyloric sphincter and 
ultimately be delivered to its specific site of absorption within the small intestines. 
 
2.2. CONSIDERATIONS FOR GASTRORETENTIVE SYSTEM DESIGN 
2.2.1. Absorption windows 
It has been observed that many drugs are only absorbed in specific regions of the 
gastrointestinal tract. These specificities may be attributed to many factors, including 
drug solubility due to varying pH’s, enzymatic degradation, interaction with 
endogenous compounds such as bile, and the necessity for active transport 
mechanisms which are only present in specific regions (Davis, 2005). 
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Drugs which display a NAW are also found to have low bioavailability when 
administered by conventional immediate release drug delivery systems. This, however, 
results in poor drug efficacy and is detrimental to overall drug therapy. Most drugs with 
a narrow absorption window are absorbed in the proximal part of the small intestines, 
or duodenum. Drugs that fall into this category include riboflavin, metformin, captopril, 
acyclovir, ciprofloxacin, levodopa and nitrofurantoin (Davis, 2005; Fukuda et al., 2006; 
Ahmed and Ayres, 2007). 
 
There are some drugs which are not suitable for use in a gastroretentive system, such 
as those which have adverse effects on the stomach lining or are absorbed equally 
throughout the entire gastrointestinal tract (GIT); however there are certain drugs 
which may benefit from being incorporated into a gastroretentive system. These drugs 
usually possess one or more of the following characteristics: local action within the 
stomach, primary absorption within the stomach, poorly soluble or unstable in the 
alkaline environment of the small and large intestines, narrow absorption window and 
rapid absorption from the GIT (Gutierrez-Rocca et al., 2003). 
 
2.2.2. Gastrointestinal transit 
In order to fully comprehend the need for gastroretentive devices and conceptualize 
their design, it is important to understand the anatomy and physiology of the stomach. 
 
The stomach is made up of three anatomical parts; the fundus, body and antrum. The 
fundus and body make up the proximal portion, acting as a reservoir for ingested 
material, while mixing and grinding occurs in the distal region (antrum) (Thibodeau and 
Patton, 1996). The pylorus is an anatomical sphincter that is situated between the 
antrum and the duodenum that serves as a sieve as well as a mechanical stricture to 
the passage of large particles into the small intestines (Thibodeau and Patton, 1996; 
Klausner et al., 2003). 
 
Gastric contents are removed from the stomach via cyclical gastric motor contractions 
(Chen et al., 2000). Gastric emptying time therefore has a huge effect on the fate of 
any oral dosage form. The process of gastric emptying occurs both in the fed and the 
fasted state; however, there are marked differences between the patterns of motility in 
both states (Singh and Kim, 2000; Klausner et al., 2003).  
 
The cyclical motor activity that occurs during the fasted state is termed interdigestive 
migrating myoelectric complex (IMMC). The IMMC follows a cycle lasting between 80 
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minutes to 2 hours, with the aim of cleaning debris from the stomach and small 
intestines (Chen et al., 2000; Singh and Kim, 2000; Klausner et al., 2003). The IMMC 
is divided into four phases. Phase 1 (basal state) is a quiescent period with only rare 
contractions, lasting 40 to 60 minutes; phase 2 (pre-burst phase) lasts 30 to 45 
minutes, showing intermittent peristaltic contractions with increasing frequency and 
amplitude; phase 3 (burst period) demonstrate intense frequent bursts of contractions 
3-5 times per minute, lasting up to 15 minutes. Phase 3 is also commonly known as 
the ‘housekeeper waves’ due to their sweeping motion. Phase 4 is the transitional 
period between phase 3 of one cycle and phase 1 of the next cycle. The IMMC begins 
in the stomach and migrates through the small intestines. As phase 3 of one cycle 
reaches the colon, the next phase 3 begins in the stomach (Chen et al., 2000; 
Klausner et al., 2003). 
 
 
Figure 2.1: The four phases of the interdigestive migrating myoelectric complex 
(Davis, 2005). 
 
The cyclical motor contractions in the fed state are initiated 5 – 15 minutes after a meal 
is ingested, lasting for as long as the food persists within the stomach, usually 3-4 
hours. The gastric residence time is related to the nutritive and physical properties of 
the food. These contractions are similar to those observed in phase 2 of the IMMC, 
and are responsible for mixing and grinding of the stomach contents. The pylorus is 
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closed, allowing only small particles to enter the duodenum, while retaining large 
particles within the stomach (Singh and Kim, 2000; Klausner et al., 2003). 
 
Gastric motility may be influenced by a variety of biological factors, including age, 
gender, posture, body position, body mass index, stress levels and disease states 
(Singh and Kim, 2000; Klausner et al., 2003), while the rate of gastric emptying of a 
dosage form will be affected by its shape, size and density as well as the concomitant 
intake of food and specific drugs (Singh and Kim, 2000). 
 
2.2.3. Dosage form factors influencing gastric residence time (GRT) 
Most of the approaches employed to attain gastroretention are influenced by a number 
of factors, namely (Garg and Sharma, 2003): 
1. Density – GRT is a function of dosage form buoyancy that is dependent on the 
density 
2. Size – dosage form units with a diameter of more than 7.5mm are reported to 
have an increased GRT compared with those with a diameter of 9.9mm 
3. Shape of dosage form – tetrahedron and ring-shaped devices are reported to 
have better GRT ≈ 90% to 100% retention at 24 hours compared with other 
shapes 
4. Single units vs. multiple units - due to the high variability in bioavailability, risk 
of local irritation and unreliable gastric prolongation, single-unit delivery 
systems are not generally preferred for controlled drug release (El-Gibaly, 
2002). It is due to this that it is preferable to utilize a multiple unit approach 
when developing a drug delivery system. The advantages of multiple units are 
most probably due to the ability of the units to pass uniformly through the 
gastrointestinal tract, and include: a more predictable drug release profile, less 
chance of localized damage to the mucosal lining, decreased risk of the 
delivery system failing, units with different release profiles can be included in 
one delivery system and no significant impairment if a few units fail to perform 
(Iannuccelli et al., 1998; Rouge et al., 1998; Goole et al., 2007). 
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2.3. COMMON BIOCOMPATIBLE POLYMERS EMPLOYED FOR THE DESIGN 
OF GASTRORETENTIVE DRUG DELIVERY SYSTEMS 
 
2.3.1. Alginate 
Alginate, a natural linear anionic co-polymeric polysaccharide that consists of 
homopolymeric blocks of (1-4)-linked b-D-mannuronic acid (M) and a-L-guluronic acid 
(G) residues linked covalently in various sequences (Figure 2.2) (Jain et al., 2005). 
The physical properties of gels that are formed render the application of alginates 
suitable for gastroretentive drug delivery. The gelation is determined by the matrix 
composition, sequence of polymer blocks and molecular mass of the alginate grade 
employed in designing the gastroretentive drug delivery system. Alginates have a wide 
range of pharmaceutical applications including thickening, gel-forming and colloidal 
stabilizing agents, binders and disintegrants in tableting and in the development of 
controlled-release gastroretentive drug delivery systems. Crosslinking of alginate can 
be initiated by polyvalent cations, resulting in the formation of gel-like matrices. 
Hydration of an alginate matrix leads to the formation of a gelatinous layer that affects 
drug diffusion by allowing drug to diffuse outward while the inner core remains 
unhydrated therefore acting as a non-releasing reservoir of drug and polymer. 
. 
 
Figure 2.2: Chemical structure of alginate depicting the homopolymeric blocks of (1-
4)-linked β-D-mannuronic acid (M) and α-L-guluronic acid (G) (Lawrie et al., 2007). 
 
2.3.2. Chitosan 
Chitosan is also a linear natural cationic binary co-polymeric polysaccharide that is 
obtained from the N-deacetylation of chitin. Chitosan consists of β-(1-4)-linked D-
glucosamine (deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit). The 
acetylated and deacetylated units are randomly distributed along the chitosan chain 
and the degree of acetylation represents the proportion of acetylated units with respect 
to the total number of units. The physicochemical properties of chitosan may be 
modified by altering the degree of deacetylation as well as the pH and ionic strength 
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during formulation. Chitosan is insoluble at neutral and alkaline pH; however it forms 
water-soluble salts with organic and inorganic acids. In an acidic medium, the amino 
groups become protonated rendering the molecule positively charged. At neutral pH, 
most chitosan molecules become non-ionic and therefore precipitate from solution. 
The biological properties of chitosan can also be modified with the attachment of 
functional groups to the chitosan polymeric chain. Chitosan has numerous beneficial 
properties for the design of gastroretentive drug delivery systems such as superior 
mucoadhesion; gelation; swelling; the ability to form films; mucosal permeation 
enhancement; tissue growth promotion and the ability to control drug release. The 
bioadhesive properties of chitosan have been extensively employed to prolong the 
gastric residence time of gastroretentive drug delivery systems (Bardonnet et al., 2006; 
Smart, 2005; Thongborisute and Takeuchi, 2008). 
 
 
Figure 2.3: Chemical structure of chitosan illustrating the β-(1-4)-linked D-glucosamine 
(deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit) (Lawrie et al., 2007). 
 
2.3.3. Hydroxypropylmethylcellulose, polyethylene oxide and polypropylene 
The most commonly used polymers in hydrophilic matrix formulations are 
hydroxypropylmethylcellulose (HPMC) and polyethylene oxide (PEO). This is due to 
their water solubility, availability in a range of molecular weight/viscosity grades, and 
their unique swelling/erosion characteristics, which are utilized in order to control drug 
release (Jamzad and Fassihi, 2006). Polypropylene foam powder is hydrophobic and 
possesses a highly porous, open-cell structure with pore sizes predominantly in the 
micro and meso-porous range with a low inherent density (0.905g/cm3) (Sher et al., 
2007). 
 
2.3.4. Ethylcellulose and hydroxypropylcellulose 
Ethylcellulose is a hydrophobic polymer used in the design of gastroretentive drug 
delivery systems to achieve sustained release of both soluble and poorly soluble drugs 
(Crowley et al., 2004). The physicochemical properties and mechanism of drug release 
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from ethylcellulose-based gastroretentive matrices are usually prepared by direct 
compression or hot-melt extrusion. Hydroxypropylcellulose (HPC) is widely used for 
the design of oral drug delivery systems. The specific uses of the various grades for 
gastroretention are dependent on their structural characteristics, i.e. as the degree of 
alkyl group substitution that may alter the polymeric interaction with gastric fluids in 
order to exploit a relevant gastroretentive mechanism. HPC grades that have a 
medium-high degree of alkyl group substitution are most suited for the preparation of 
matrix tablets, whereas grades with a lower degree of substitution have superior 
swelling dynamics.  
 
2.3.5. Polymethacrylates 
Polymethacrylates (Eudragit®) is commonly used as a retardant in controlled release 
drug delivery systems. Eudragit® RS functions to retard drug release when melted 
above its glass transition temperature (Fukuda et al., 2006). The pH of the GIT 
environment in which gastroretention is intended, results in the polymer acting as a 
polyelectrolyte, making them suitable for altering the gastric residence time through 
mucoadhesion, gelation, solubility and density variation. Various Eudragit® grades 
have been employed for the design of gastroretentive drug delivery systems such as 
Eudragit® E, RL, RS, and NE that are polycations, while Eudragit® grades L and S are 
polyanions (Bardonnet et al.,  2006; Jain et al., 2005; Moustafine et al., 2005). 
 
2.4. MECHANISTIC ATTEMPTS AT GASTRIC RETENTION  
Various polymeric drug delivery systems have been developed that attempt to exploit 
the anatomy and physiology of the GIT environment. These include buoyant systems, 
bioadhesive systems, high density systems, modified shape systems, gastric-emptying 
delaying devices and co-administration of gastric-emptying delaying drugs (Figures 2.4 
and 2.5). Among these, buoyant drug delivery systems have been used most often. 
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Figure 2.4: Classification of gastric retentive systems. 
 
 
Figure 2.5: Schematic depicting mechanisms of retention of: a) Low density buoyant 
system b) High density system c) Mucoadhesive system d) Swelling/Expanding 
system. 
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2.4.1. Floating systems 
Buoyant drug delivery systems are by far the most commonly researched mechanisms 
of achieving gastric retention. In order for a drug delivery system to achieve buoyancy 
an intimate balance between the weight and volume of the system is required. To 
obtain immediate buoyancy, the delivery system should have an original density of 
less of than 1g/cm3. One of the major advantages of utilizing a buoyant drug delivery 
system is the ability to achieve an increase in gastric residence time without altering 
the intrinsic rate of gastric emptying (Stithit et al., 1998; El-Gibaly, 2002). Several 
factors have been found to influence the buoyancy of a drug delivery system, including 
mass, density, diameter, nature of excipients, grade of polymers used and the pH of 
gastric fluids (Singh and Kim, 2000). Numerous novel methods have been developed 
in order to achieve buoyancy.  
 
2.4.1.1. Low density systems 
2.4.1.1.1. Highly porous system 
The inclusion of low density polymeric carriers in a formulation may result in a matrix 
with a density of less than 1g/cm3, thereby becoming buoyant. There are numerous 
low density carriers available, including porous silicon dioxide, polypropylene foam, 
magnesium aluminometa silicate, porous calcium silicate (Jain et al., 2005) and 
polypropylene foam powder (Streubel et al., 2002; Sher et al., 2007). These porous 
carriers possess certain characteristics which add to their attractiveness for use in 
drug delivery system design, including a high surface area, tunable pore sizes with 
narrow distributions, stable uniform porous structures and well-defined surface 
properties thus allowing for the absorption of drugs and drug release in a reproducible 
and predictable manner (Sher et al., 2007). 
 
Streubel et al. (2002) formulated microparticles using a solvent evaporation method. 
Polypropylene foam powder was dispersed within the organic phase. The resultant 
microparticles still displayed a high porosity and more than 83% of the particles 
remained buoyant for at least 8 hours. 
 
Jain et al. (2005) utilized calcium silicate, a highly porous structure for the 
development of a buoyant system intended for the delivery of repaglinide. Drug was 
initially adsorbed onto the calcium silicate through ultrasonication. Drug adsorbed 
calcium silicate was then used to create the highly porous microspheres. This system 
displayed good buoyancy and excellent drug entrapment. 
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Sher et al. (2007) combined the principles of floating and pulsitile systems in order to 
achieve a gastroretentive, chrono-therapeutic drug delivery system. Porous beads 
were formed by way of melt and solvent evaporation. Both of these methods involved 
a single step and multiple absorption technique with the inclusion of Accurel MP 
1000®, a low density polypropylene foam powder. 
 
Besides using a highly porous carrier, pores may also be incorporated within a 
gastroretentive drug delivery system just before crosslinking occurs. Badve et al. 
(2007) employed pectin and sodium bicarbonate in order to produce hollow porous 
floating beads. Sodium bicarbonate is incorporated into the polymeric solution, 
resulting in the generation of CO2 gas when it comes into contact with the acid medium 
of the crosslinking solution. The small pockets of gas become entrapped within the 
beads during crosslinking, resulting in a highly porous bead. 
 
Another method of obtaining a highly porous matrix is to include lyophilization within 
the formulation process. Due to the mechanics of the process, sublimation of water 
occurs, resulting in a stable, yet porous structure. The increased porosity results in a 
reduction in density of the system thereby facilitating floatation. Whitehead et al. 
(2000) prepared beads by crosslinking sodium alginate with calcium chloride which 
were subsequently frozen and lyophilized. In vivo studies revealed that the lyophilized 
beads remained buoyant for extended periods of time, and the concurrent intake of 
food enhanced buoyancy. 
 
2.4.1.1.2. Air compartment/Microballoons 
In order to ensure immediate buoyancy of a drug delivery system, an air compartment 
(or buoyancy chamber) can be incorporated within the system. This process, however, 
is generally complex and complicated. 
 
Iannuccelli et al. (1998) were able to successfully design a delivery system involving a 
much simpler approach. Units, consisting of a core, separated from a membrane by an 
air compartment, were prepared by coating a calcium alginate core with a membrane 
formed from a blend of calcium alginate and polyvinyl alcohol. An air compartment 
formed between the core and the membrane due to shrinkage of the core during the 
drying process. In vitro tests revealed 100% immediate buoyancy, lasting for more 
than 24 hours. It was observed during in vivo human studies that the delivery system 
achieved effective buoyancy for extended periods of time, and that buoyancy was 
improved with the concurrent intake of food (Iannuccelli et al., 1998). 
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Chitosan, which has played an important role in the design of controlled release drug 
delivery systems, crosslinks with multivalent counter-ions via ionotropic gelation to 
form microspheres. Kas (2007) reported that these microspheres displayed a limited 
strength and poor buoyancy. El-Gibaly (2002), however, was able to develop hollow 
chitosan microspheres through the interaction with a negatively charged surfactant, 
sodium dioctyl sulphosuccinate, leading to the formation of chitosan gel sacs that were 
insoluble at a low pH (Sato et al., 2003).  
 
Sato et al. (2003) developed a multiple-unit intragastric floating system involving 
hollow microspheres or microballoons, by solvent diffusion. It was observed that the 
temperature at which the microspheres were prepared had an appreciable effect on 
the buoyancy, drug release and friability. Further investigations through 
pharmascintigraphic evaluation demonstrated gastric retention of up to 300 minutes 
following administration (Sato et al., 2004). 
 
Hollow microspheres are currently considered to be one of the most promising 
systems intended to maintain buoyancy. This is due to their inherent superior 
buoyancy in combination with a multi-unit system (Bardonnet et al., 2006). 
 
2.4.1.2. Hydrodynamically balanced systems  
A hydrodynamically balanced system is a single-unit delivery system. Low density, 
hydrophilic polymers are blended with the drug and usually added to empty gelatin 
capsules. Once in contact with gastric fluids, the capsule dissolves and exposes the 
polymeric blend, allowing for hydration and swelling to occur. Due to the low densities 
of the polymers, the swollen mass floats on the surface of the gastric contents. Various 
excipients may be incorporated in order to delay the erosion of the system (Bardonnet 
et al., 2006).  
 
Ali et al. (2007) investigated the release of metformin via this approach. Varying 
concentrations of hydroxypropylmethyl cellulose (HPMC) and polyethylene (PEO) 
were investigated, as well as the effect of various release modifiers, including 
ethylcellulose, cellulose acetate phthalate (CAP) and liquid paraffin. A zero order 
release was achieved and the drug delivery system remained buoyant for 12 hours. In 
vitro studies showed an increase in drug absorption compared to an immediate 
release capsule. 
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2.4.1.3. Effervescent tablets 
Sodium bicarbonate, citric acid and tartaric acid generate carbon dioxide (CO2) gas 
which may be entrapped within the system matrix once in contact with acidic gastric 
contents.  The release of CO2 gas therefore results in an upward motion maintaining 
buoyancy of the system (Singh and Kim, 2000). These CO2 generating components 
are incorporated in a tablet matrix in one of two forms, either intimately incorporated 
within the matrix, or separated within its own layer as depicted in Figure 2.6 
(Bardonnet et al., 2006). 
 
Ichikawa et al. (1991) developed a double layered granular system incorporating a 
core of bicarbonate and tartaric acid, each formed separately in sub-layers in order to 
prevent direct contact. The system was fully buoyant within 10 minutes due to the 
formation of a balloon-like swollen tablet with a density of less than 1g/ cm3. This 
system was observed to be successful over a range of pH values. 
 
Bicarbonate loaded microparticles, coated with an ion-exchange resin containing 
theophylline, have been formulated by Atayabi et al (1996). The microparticles were 
then coated with a semi-permeable coating, thereby allowing the permeation of gastric 
fluid which resulted in an exchange of chloride and bicarbonate ions. The generated 
CO2 gas became trapped within the membrane, thereby resulting in buoyancy of the 
system. 
 
There are, however, a few disadvantages related to effervescent drug delivery 
systems. A notable disadvantage is that the rate and degree of effervescence are 
highly pH dependent, and is easily affected by the intake of food and certain disorders 
such as achloraemia. Another disadvantage is that the delivery system may be 
prematurely removed from the stomach due to its lag phase, prior to becoming 
buoyant (Fukuda et al., 2006). 
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Effervescent component
Polymer-drug matrix
 
Figure 2.6: Schematic of a) a single layer tablet matrix, b) a bi-layered tablet and c) a 
bi-layered tablet with a central effervescent core. 
 
2.4.1.4. Hot-melt extrusion 
Hot melt extrusion is a method of continuous mixing and design of mouldable 
materials. It is possible to produce tablets, microspheres, granules, transdermal and 
transmucosal delivery systems through this process (Mididoddi and Repka, 2007). 
Polymethacrylate (Eudragit®) polymers are the most commonly used polymers for this 
approach, due to their thermoplastic properties. When selecting a polymer, it is 
important to consider the glass transition temperature, melt viscosity and stability 
under high temperatures. Hot-melt extrusion is associated with numerous advantages. 
These advantages include fewer steps involved, the absence of solvents, no need for 
compression and thorough mixing of formulatory components (Bruce et al., 2005; 
Mididoddi and Repka, 2007). 
 
Fukuda et al.(2006) utilized a single screw extruder in order to produce the excrudates, 
which, once at room temperature, were then cut into tablets. Sodium bicarbonate was 
included in the formulation that underwent thermal degradation resulting in the 
generation of CO2 gas. The CO2 became entrapped within the tablet matrix, resulting 
in a highly porous, buoyant tablet. However, due to the pH dependence associated 
with the generation of CO2 gas the delivery system was not suitable for achlorhydric 
patients, who have a high fasted gastric pH value (pH=7). 
 
2.4.2. High density systems 
The density of gastric fluid is roughly 1.004g/cm3 (Bardonnet et al., 2006). Pellets with 
a density of between 2.4 and 2.8g/cm3 have been found to sink to the bottom of the 
stomach when the patient is in the upright position. The pellets become entrapped 
within the folds of the mucosa, therefore withstanding the effects caused by peristalsis 
(Clarke et al., 1993). Rouge et al. (1998) conducted a comparative study with an 
immediate release system, a high density system and a low density system. The 
results showed gastric residence times of 0.5, 1 and 2 hours respectively, indicating 
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that the high density system did not demonstrate any significant extension of gastric 
residence time. Excipients which are commonly used in order to increase the density 
of drug delivery systems include: barium sulphate, zinc oxide, iron powder and titanium 
dioxide (Bardonnet et al., 2006). Although high density drug delivery systems have not 
shown remarkable significance for the delivery of drugs to a human model, success 
has been illustrated with the administration of pellets with a density of 2.0g/cm3 in the 
bovine model (Rouge et al., 1998). 
 
2.4.3. Magnetic systems 
Gröning et al. (2007) designed a novel drug delivery system by incorporating a small 
magnet within the delivery system, and guiding it with an extracorporal magnet 
attached to the abdomen. The capsule was effectively delayed within the stomach, 
therefore extending the gastric residence time and increasing the absorption of the 
drug at its specific absorption window. It was however found that results differ, 
depending on whether the patient is in a fed or fasting state. A high patient variability 
has been observed due to variability in gastric motility and peristaltic waves (Gröning 
et al., 2007). Clinical investigations were conducted involving three different delivery 
systems. The first system involved the magnetic depot tablet with the use of the 
extracorporal magnet, the second system excluded the use of the extracorporal 
magnet and the third system was an immediate release formulation. A gastric retention 
time of 12 hours was obtained, and drug plasma concentrations showed an increase in 
drug absorption associated with the magnetic depot tablet when the extracorporal 
magnet was used. The most probable system limitation associated with a magnetic 
system is the reduced patient compliance due to the precision with which the magnet 
must be placed externally (Bardonnet et al., 2006). 
 
2.4.4. Mucoadhesive systems 
The basis of mucoadhesive systems is that the delivery system adheres to a site in the 
gastrointestinal tract, thereby extending the residence time. Research into 
mucoadhesive drug delivery systems first began in the field of ophthalmics (Bernkop-
Schnürch, 2005), but has to date shown the potential to prolong residence times of 
nasal (Tafaghodi et al., 2004), ocular (Hornof et al., 2003), buccal (Korbonits et al., 
2004) and vaginal (Kast et al., 2002) drug delivery systems. 
 
The first generation of mucoadhesive polymers were hydrophilic macromolecules 
containing numerous hydrogen bonding groups. These include chitosan, carbomers 
and sodium alginate (Smart, 2005). These polymers become adhesive on exposure to 
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moisture and adhere non-specifically to bio-surfaces, although adhesion is greater 
when in contact with a dry, inert surface. The various types of bonds involved in 
mucoadhesion include hydrogen bonds, ionic bonds, covalent bonds, van der Waals 
forces and hydrophobic bonds. There are many theories which have been 
hypothesized as to the mechanism of mucoadhesion. Although a definite mechanism 
has not been proven to be true for all scenarios, two steps have been identified in the 
process of adhesion, namely the contact stage and the consolidation stage (Figure 
2.7). The contact stage involves the wetting of the mucoadhesive surface, which 
comes into intimate contact with the mucous membrane. The consolidation stage 
involves the physicochemical interactions that occur in order to consolidate and 
strengthen the adhesive joint, resulting in a prolonged adhesion. 
 
 Drug Delivery 
System Contact  
Stage 
Gastric mucosa with 
mucus layer 
Consolidation  
Stage 
 
Figure 2.7: The two stages involved in mucoadhesion (Smart, 2005). 
 
Chavanpatil et al. (2006) developed a delivery system comprising HPMC and psyllium 
husk for the delivery of ofloxacin. It was observed that both the HPMC and psyllium 
husk displayed significant bioadhesivity and resulted in enhanced gastroretention. 
 
Säkkinen et al. (2003) investigated the use of microcrystalline chitosan as a 
mucoadhesive agent. Although all grades were found to be adhesive, further 
investigation revealed that microcrystalline chitosan with the largest molecular mass 
displayed the greatest adhesion. In vivo studies, however, did not produce evidence 
that the system provided gastric-retention in humans. 
 
Illum et al. (2001) have formulated a mucoadhesive microsphere intended for the local 
treatment of Helicobacter pylori.  The microspheres are formed through the process of 
spray drying and comprise an inner core containing drug, a rate controlling layer of 
water insoluble polymer and an outer bioadhesive layer. 
 
Tur and Ch’ng (1998) investigated whether there was a relationship between the 
bioadhesivity of a polymer and its zeta potential. Different polymers were synthesized 
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and swelling, bioadhesivity and zeta potential studies were conducted. The results 
were correlated and it was confirmed that a relationship existed. It is believed that the 
zeta potential may provide the initial driving force for bioadhesion, followed by 
interpenetration and the subsequent secondary bonds. The study also indicated the 
importance of the degree of ionization of the polymer. 
 
Thongborisute and Takeuchi (2008) have developed a method for measuring the 
mucoadhesive properties of polymers (Figure 2.8). This method involved measuring 
the change in particle size and zeta potential of mucin particles after the addition of a 
polymer. A large change in what is termed the RU response signified stronger 
mucoadhesive properties. 
 
 Polymer 
Most mucoadhesive Chitosan 
 Carbopol 971 PNF 
Carbopol 974 PNF 
Low molecular weight 
Chitosan 
HPMC 
PVP 25 
Least mucoadhesive PVA 205 
Figure 2.8: Rank order of strength of mucoadhesiveness of a selection of polymers 
(adapted from Thongborisute and Takeuchi, 2008). 
 
Existing molecules are currently being modified in order to increase their 
mucoadhesive properties. An example of this which is growing in popularity is the 
thiolation of polymers. This results in the in-situ formation of disulfide bonds, not only 
between the polymers, but also between the polymers and the mucus membrane, thus 
resulting in the strengthening of the mucoadhesivity. This has been applied to chitosan 
(Guggi et al., 2003), alginates, carbomers (Bernkop-Schnürch, 2005), polycarbophil 
(Kast et al., 2003) and poly(acrylic) acid (Caliceti et al., 2004)  
 
The major limitation to mucoadhesive drug delivery systems is the natural turnover of 
mucus, which occurs between every 12 to 24 hours within the stomach (Bernkop-
Schnürch, 2005; Bardonnet et al., 2006).  
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2.4.5. Expanding systems 
Expanding drug delivery systems are retained within the stomach due to their size 
which is larger than the diameter of the pyloric sphincter, thereby inhibiting its transport 
into the intestine. When developing an expanding drug delivery system, there are a 
few criteria which should be met (Klausner et al., 2003; Bardonnet et al., 2006; 
Gröning et al., 2007). These criteria include: a) the delivery system should be small 
enough and convenient to swallow, b) it should expand rapidly to an effective size so 
as to prevent premature evacuation from the stomach and c) the delivery system 
should degrade in order to prevent a luminal blockage. It has been suggested that the 
minimum size required in order to be retained within the stomach is a length of at least 
5cm or a diameter of 3cm (Klausner et al., 2003). Expanding gastroretentive drug 
delivery systems have been utilized by the veterinary sector for numerous years and 
was first developed by Laby in 1974 for the prevention of bloat in ruminants. 
Consequent to that, much more extensive research was conducted within the 
veterinary sector (Brewer and Griffin, 1980; Griffin and Brewer, 1981).  
 
Expansion of the delivery systems is achieved by two mechanisms namely swelling 
and unfolding. Both these mechanisms result in an increase in size which inhibits the 
passage of the delivery system through the pyloric sphincter into the intestine. Swelling 
occurs due to the absorption of water, usually by osmosis, whereas unfolding occurs 
due to the mechanical shape memory of the pharmaceutical carrier. 
 
Swelling systems demonstrate an additional benefit over other gastroretentive delivery 
systems, due to the bulk of the system located within the stomach; a “fed” state is 
maintained, resulting in the suppression of housekeeper waves, offering a prolonged 
period of gastric retention (Bardonnet et al., 2006). Mamajek and Moyer (1980) 
patented a drug reservoir surrounded by an elastic and swellable membrane that is 
permeable to the drug and body fluids, thereby controlling the rate of release of the 
drug. Due to the absorption of fluids causing an osmotic pressure within the drug 
reservoir, the drug was released. Due to the loss of the drug and expanding agent the 
size eventually decreases, allowing its evacuation.  
 
Urquhart and Theeuwes (1984) developed a system consisting of tiny wax coated 
tablets, controlling the rate of drug release. The tablets were then dispersed within a 
polymeric hydrogel. In the stomach, the system swelled up to 50 times its original 
volume, allowing the drug to release from the tiny tablets. The system left the stomach 
after hydrolysis and bioerosion had occurred.   
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Gröning et al. (2007) developed a swelling gastroretentive delivery system based on 
the compression of a drug-loaded collagen sponge. The collagen had been initially 
freeze-dried, resulting in a porous and spongy structure. The collagen was then 
compressed using both a pneumatic pump and a tablet press. The surface of the 
collagen was coated with a thin layer of magnesium stearate, allowing the delivery 
system to remain stable when in contact with saliva. On contact with the gastric fluids, 
the tablet expanded to almost its original size. Both the rate and extent of expansion is 
pH dependant. Although the final volume was slightly smaller in an acidic environment, 
the expansion occurred at a much faster rate. In vivo studies demonstrated that the 
duration of gastric residence was extended and disintegration was observed after 180 
minutes. 
 
Edgren et al. (2004) patented a multiple layered delivery system formed from polymers 
which swell in the presence of gastric fluids. The rigidity of the system is maintained by 
covering a portion of the matrix with a band of insoluble material, thereby preventing 
that specific portion from swelling. 
 
Shell and Louie-Helm (1999) developed a method of incorporating drug loaded 
liposomes and nanoparticles, or enteric coated drug particles into a swellable/erodible 
polymer, which can be made into a tablet or capsule. On contact with gastric fluids, the 
capsule or tablet disintegrates, allowing the polymer to swell. Erosion occurs over an 
extended period of time, releasing the drug in a controlled manner.  
 
Unfolding systems should demonstrate specific properties in order to be effective and 
non-hazardous to the patient. These properties include: resistance to forces within the 
stomach; allowance for unhindered passage of food through the stomach while in 
residence; expansion to a circumference of greater than 5cm and flexible enough not 
to puncture the gastrointestinal wall (Curatolo et al., 1995; Klausner et al., 2003).  
 
Caldwell et al. (1988) proposed and evaluated different geometric shapes of 
bioerodible polymers which could be compressed within a tablet or folded into a 
capsule. These shapes included the tetrahedron, ring or planar membrane (Figure 
2.9).  
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4-Lobed Discoid 4-Limbed cross Ring Tetrahedron  
Figure 2.9: Different geometric forms of unfoldable systems (Source: Bardonnet et al. 
2006). 
 
Krumme (2004) has patented a triangular shaped drug delivery system with an internal 
drug compartment. When the device comes into contact with gastric fluid, it unfolds 
and its shape prevents passage through the pylorus. Asmussen et al. (2001) 
formulated an expanding drug delivery system, comprising multiparticulate drug 
dispersed within the expandable component, and covered with a polymer, creating a 
membrane which is permeable to gastric juice and the active compounds. Kagan et al. 
(2006) developed an Accordion PillTM which comprises three layers, a central layer 
providing the frame sandwiched between two envelope membranes, and the drug 
reservoir in the centre. In vivo studies demonstrated that the concurrent intake of a 
high calorie meal was not necessary for this particular delivery system. This is a huge 
accomplishment as the retention times of gastroretentive drug delivery systems are 
detrimentally affected by the fasted state.  
 
Sonobe et al. (1991) developed an unfolding “Y” system demonstrating prolonged 
shape memory (Figure 2.10) in which the centre of the “Y” was comprised of a polymer 
which was able to maintain its shape memory for an extended period of time, while the 
limbs of the “Y” consisted of a drug-loaded erodible material, the rate of erosion of 
which determines the residence time. A third component provided the link between the 
centre and the limbs. Curatolo et al. (1995) developed a spiral configuration 
comprising four short shape memory arms arranged concentrically around a tablet. As 
seen in Figure 2.10, a shape memory material (a), which assures unfolding, is 
connected to the erodible material which serves as a drug reservoir (b) and whose rate 
of degradation controls the gastric retention time. Both of these systems achieved a 
gastric retention of longer than 24 hours in in vivo animal studies. 
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Figure 2.10: Diagrammatic representation of: a) The spiral configuration unfolding 
system developed by Curatolo et al., 2005, and b) The unfolding ‘Y’ system developed 
by Sonobe et al.,1991 (Source: Klausner et al., 2003).  
 
Gastroretentive delivery systems are currently in use as medical devices within Europe 
for the treatment of overweight patients. This indication is due to the bulk effect within 
the stomach, resulting in a feeling of satiety and reduced hunger (Gröning et al., 2007). 
 
Despite the interest that expandable systems have attracted, there are still a few 
drawbacks associated with the unfolding systems which have to be considered. The 
most important is that this type of system is difficult to manufacture and is not cost-
effective. Furthermore, the mechanical shape memory of the polymers is relatively 
short-lived and due to the prolonged storage of the drug delivery systems, the efficacy 
of the unfolding process may be compromised (Bardonnet et al., 2006). 
With reference to the swelling systems, commercialization of the technology is 
considerably simpler, and stands a better chance of entering the clinical setting 
(Klausner et al., 2003). 
 
2.4.6. Superporous hydrogel 
The superporous hydrogel is a novel expanding system which is currently being 
researched by Chen et al. (2000). It is due to the unique characteristics associated 
with these superporous hydrogels that they are classified as a new mechanism of 
gastric retention. The superporous hydrogel, when dried, contains open pores which 
form capillary channels. It is due to these open pore channels within the dehydrated 
hydrogel, through which water is rapidly absorbed which allows swelling to take place 
within a few minutes, up to a few hundred times its original volume. The most unique 
aspect of the superporous hydrogel is that the average pore size is usually in the 
range of a few hundred micrometers. On hydration, water is taken up by capillary 
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wetting as opposed to diffusion. In order to increase the mechanical strength of the 
hydrogels to withstand peristaltic pressure, the superporous hydrogel composites were 
synthesized by adding croscarmellose sodium (Ac-Di-Sol®; FMC Biopolymer). 
Superporous hydrogels can be divided into two groups, which are differentiated by 
their swelling ratio and their mechanical stability. A superporous hydrogel or SPH is a 
soft polymer which swells very quickly, but has poor mechanical stability, whereas a 
superporous hydrogel composite (SPHC) has a slower swelling rate, but is 
mechanically stable. The SPHC is therefore utilized as a retentive drug delivery 
system (Dorkoosh et al; 2004).  
Through the incorporation of biodegradable crosslinkers, the superporous hydrogel will 
degrade in the body, thus preventing obstructions within the gastrointestinal tract. In 
vivo animal studies demonstrate that the superporous hydrogel remained within the 
stomach for more than 24 hours after feeding. After about 30 hours there was 
evidence of fragmentation and the delivery system was cleared from the stomach 
(Chen et al., 2000).  
 
2.4.7. Naturally or pharmaceutically altering gastric emptying 
2.4.7.1. Pharmaceutical 
A rather simple method to improve gastric retention involves the inclusion of either an 
excipient or pharmaceutical substance which possesses gastric motility retardation 
characteristics.  
 
Stops et al. (2006) investigated the use of citric acid to prolong the gastric residence 
time of floating calcium alginate beads. It has been proposed that the intake of citric 
acid decreases duodenal pH to below 6, thereby halting gastric motility. A negative 
feedback system is thus activated to restore the pH, allowing gastric emptying to re-
commence (Hunt and Knox, 1962). In vivo studies demonstrated that citric acid 
effectively delayed gastric emptying in the fasted state.  
Osinski et al. (2002) conducted studies on the gastric emptying rate of mice. It was 
observed that metaclopramide and bethanechol display an increase in gastric 
emptying, while propantheline, an anticholinergic compound and CRF (corticotrophin 
releasing factor), a hypothalamic hormone, resulted in increases in gastric emptying 
time. Marathe et al. (2000) conducted human studies in order to determine the effect of 
metaclopramide and propantheline on the absorption of metformin. The results 
obtained suggested that metaclopramide did not affect the absorption of metformin as 
it resulted in a decrease in gastric emptying time, while pre-treatment with 
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propantheline actually resulted in an increased absorption due to the prolongation of 
gastric emptying time. 
 
2.4.7.2. Biological 
Certain dietary components, such as fats, peptides and some amino acids, posses the 
characteristic of prolonging gastric emptying and intestinal transit. This phenomenon is 
known as the ileal brake, which is believed to be a feedback process in order to 
improve digestion of dietary components.  
 
Components from other biological species have been investigated for their ability to 
delay gastric and intestinal transit.  
 
It is known that tapeworms decrease intestinal transit in hosts. For this reason, 
Kroening et al. (2003) investigated the effect of compounds excreted by tapeworms 
and concluded that cGMP is most likely responsible for this delay. It was therefore 
suggested that the addition of cGMP into pharmaceutical formulations may improve 
drug absorption. 
 
Groups of researchers have investigated the use of plant lectins and purified fimbriae 
of E. Coli in order to increase bioadhesivity of microspheres. Studies conducted on 
both of these investigations have revealed supporting data (Illum and Ping, 1998; 
Montisci et al., 2001; Davis, 2005). 
 
2.4.8. Combinations of gastroretentive mechanisms 
Researchers have recently been investigating the possible advantages of combining 
more than one mechanism of gastroretention in order to achieve an additional 
enhancement and prolongation of gastric residence time (Chueh et al., 1995; 
Chavanpatil et al., 2006). 
 
2.5. VISUALIZATION OF GASTRORETENTIVE DRUG DELIVERY SYSTEMS 
Visualization is a vital step in the development of a novel gastroretentive drug delivery 
system. Many methods have been used in order to clearly see the positioning and 
characteristics of gastroretentive systems, although the following four techniques may 
produce superior results: 
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2.5.1. Radio-labeling and γ-scintigraphy 
A radioactive isotope which emits γ-rays is incorporated into the formulation (Klausner 
et al., 2003). The most commonly used radioisotope is technetium (Tc99m), which is 
prepared through the elution of pertechnetate (TcSO4-99m) with a 0.9% sodium 
chloride solution from a molybdenum-99 generator (Badve et al., 2007). The major 
advantages of using Tc99m are its short half-life of 6 hours, very low radiation dose 
and its easy availability in a sterile, pyrogen free and carrier free state (Ali et al., 2007). 
When the γ-scintigraphy is performed, the location of the delivery system can easily be 
observed. 
 
2.5.2. Radiology 
Through the incorporation of radiopaque threads, such as barium sulphate (BaSO4), it 
is possible to determine the positioning and movement of delivery systems from x-rays 
taken at different time periods (Chen et al., 2000; Hoffman et al., 2004). Radiology is 
commonly used in preclinical trials due to its simplicity and cost effectiveness. 
However, due to health risks from high levels of exposure, its use has become limited 
and γ–scintigraphy may be preferred (Klausner et al., 2003).  
 
2.5.3. Magnetic resonance imaging (MRI) 
MRI’s may be performed in order to improve the visualization of delivery systems 
within the stomach. These scans are normally done in the supine position, and scans 
are taken in both the axial and coronal planes (Kagan et al., 2006). Sequential images 
may assist in the determination of gastric retention. 
 
2.5.4. Multichannel superconducting quantum interference device (SQUID) 
Newer, non-invasive and radiation free methods, known as biomagnetic techniques 
have been developed for the evaluation of delivery systems. Multichannel 
superconducting quantum interference device (SQUID) devices measure the magnetic 
field of an ingested delivery system which is magnetically marked. Although the 
SQUID has expensive operating costs, it is designed to detect extremely weak 
biomagnetic fields, in a magnetically shielded environment (Cora´ et al., 2007). 
 
2.5.5. Alternate current biosusceptometry (ACB) 
A new promising technique, the alternate current biosusceptometry (ACB), has shown 
accuracy in the evaluation of physiological properties of the GI tract. Induction coils are 
used to record the magnetic flux variation obtained by the response of an ingested 
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magnetic material (ferrite—MnFe2O3). Continuous improvements of the ACB has 
allowed for the gradual increase of sensitivity (Cora´ et al., 2007). 
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CHAPTER 3 
Development, Design and Optimization of Gastrospheres 
 
3.1. INTRODUCTION 
Metformin hydrochloride is a di-substituted biguanide (N-1,1-dimethylbiguanide) anti-
hyperglycaemic agent used in the treatment of Type II non-insulin-dependent diabetes 
mellitus. It is highly water-soluble and has a relatively low bioavailability of 50% as well 
as a short, variable biological half-life of 0.9–2.6 hours. Gastrointestinal absorption is 
completed after 6 hours with peak plasma concentrations reached after 2–3 h (Corti et 
al., 2008; Porta et al., 2008). Initial doses start between 500mg administered twice a 
day or 850mg once a day. With a maximum dosage of 3g per day administered in 
divided doses (South African Medicines Formulary, 2010). 
 
Alginate is a linear copolymer made up of β-D-mannuronic acid and α-L-guluronic acid 
in different configurations (Tu et al., 2005; Xu et al., 2007). The carboxyl groups 
present on the alginate molecule is responsible for its pH-sensitive nature (Xu et al., 
2007). Contact with a multivalent cation such as calcium results in instantaneous 
gelation (Tu et al., 2005). This gelation process can be explained through the egg-box 
model where the carboxylic acid groups of two adjacent alginate molecules are bound 
by the multivalent ion (Tu et al., 2005; Al-Kassas et al., 2007). Pectin, a naturally 
occurring polysaccharide, mainly consists of α-(1,4)-galacturonic acid. The 
characteristics of pectin are highly dependent on its level of esterification and gels in 
the presence of particular multivalent ions such as calcium through the binding of 
galacturonic acid on adjacent chains (Itoh et al., 2007). This gelation process reduces 
hydration and results in a more stable molecule at low pH’s (Wei et al., 2006). 
 
Polyacrylic acid (PAA) is commonly used in drug delivery systems due to its 
biocompatibility, mucoadhesivity, unique properties and multifunctional nature 
(Khutoryanskiy, 2007; Jin et al., 2009). The mucoadhesive properties of PAA is due to 
hydrogen bonding with mucin in the gastrointestinal system (Jin et al., 2009). At low 
pH’s, such as within the gastric region, carboxylic acid groups on the PAA chain are 
non-ionised, displaying the strongest mucoadhesion (Khutoryanskiy, 2007). Poly-
lactic-co-glycolic acid (PLGA) is widely used in the area of pharmaceutical drug 
delivery due to its good biocompatibility, toxicity and biodegradation profiles (Mok and 
Park, 2008; Klose et al., 2010) and is one of very few synthetic polymers approved for 
human use (Klose et al., 2010). 
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The purpose of this chapter therefore, was to design and optimize a gastrofloatable 
and gastroadhesive multi-particulate drug delivery system for the delivery of model 
narrow absorption window drug, metformin, with the use of a Box-Behnken 
experimental design. Parameters which were evaluated include the yield, drug 
entrapment efficiency, in vitro drug release in simulated gastric fluid, buoyancy, 
gastroadhesion, swelling studies, surface area and porosity analysis as well as an 
investigation of transitions that might have occurred within the polymeric sphere. 
 
3.2. MATERIALS AND METHODS 
3.2.1. Materials 
The following materials were all of analytical grade and used as received. The 
polymers used were Sodium alginate (ALG) (Protanal LF 10/60®; FMC BioPolymer, 
Drammen, Norway), pectin (PEC) (classic CU 701®; Herbstreith & Fox, Neuenbürg, 
Germany), polyacrylic acid (PAA) (Carbopol 974P NF®;Noveon, Cleavland, Ohio, USA) 
and  poly lactic-co-glycolic acid (PLGA) (Resomer RG 858 S®) (Boehringer Ingelheim 
Pharma, Ingelhiem, Germany). 1,1-Dimethylbiguanide hydrochloride (metformin) was 
purchased from Aldrich (St Louis, MO, USA). Calcium hydroxide was purchased from 
BDH Chemicals Ltd. (Poole, Dorset, UK) and dichloromethane which was used as a 
solvent (Merck Chemicals Ltd, Wadeville, Gauteng, South Africa). All other reagents 
used were of analytical grade and were employed as purchased. 
 
3.2.2. Methods 
3.2.2.1. Construction of a randomized Box-Behnken experimental design 
A randomized Box-Behnken statistical experimental design was constructed (Minitab® 
V15, Minitab Inc., PA, USA) in order to model the number of formulations required for 
optimization as well as to establish the interaction effects of the independent 
formulation variables on the physicochemical and physicomechanical properties of the 
gastrospheres. Experimental trials were performed on 15 statistically-derived 
formulations of various combinations. Alginate, pectin, PAA (1-2%w/v) and PLGA (0-
2%w/v) were selected as the independent formulation variables, with alginate and 
pectin at a ratio of 1:1, and the Mean Dissolution Time at 12 hours (MDT12). The 
strength of gastroadhesion was selected as the formulation response. A statistical 
model incorporating interactive and polynomial terms was utilized to evaluate the 
responses. Response surface plots were constructed to visually represent the 
influence of the polymeric concentrations on the metformin release dynamics from the 
crosslinked gastrospheres. 
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3.2.2.2. Preparation of gastrospheres 
Gastrospheres were prepared by crosslinking and subsequent lyophilization using a 
combination of polymers in accordance with the Box-Behnken experimental design 
(Table 3.1).  
 
Table 3.1: Box-Behnken design template with randomly generated formulations. 
Gastrosphere 
Formulations 
[Alginate] 
(%) 
[Pectin] 
(%) 
[PAA] 
(%) 
[PLGA] 
(%) 
1 1.0 1.0 2.0 1.0 
2 2.0 2.0 1.5 2.0 
3 1.0 1.0 1.5 2.0 
4 1.5 1.5 1.5 1.0 
5 1.5 1.5 2.0 0.0 
6 2.0 2.0 2.0 1.0 
7 1.0 1.0 1.5 0.0 
8 1.5 1.5 1.5 1.0 
9 1.5 1.5 1.0 0.0 
10 2.0 2.0 1.0 1.0 
11 1.5 1.5 1.0 2.0 
12 1.5 1.5 1.5. 1.0 
13 1.5 1.5 2.0 2.0 
14 1.0 1.0 1.0 1.0 
15 2.0 2.0 1.5 0.0 
 
Fifteen polymeric solutions of alginate, pectin, PAA and metformin were dissolved in 
100mL water, and PLGA was dissolved in 5mL dichloromethane. Both polymeric 
solutions were combined and allowed to stir for 1 hour until a homogenous state was 
achieved. The combined polymeric solution was injected drop wise into a crosslinking 
solution of 2%w/v calcium hydroxide (500mL). Gastrospheres were allowed to cure for 
20 minutes, after which they were removed from the crosslinking solution, washed 
three times with 500mL deionized water and frozen at -72°C for 24 hours. Frozen 
gastrospheres were lyophilized (Labconco, Missouri, USA) with a 2 hour condensation 
phase at -60°C and a 24 hour sublimation phase at 25 mmtor. 
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3.2.2.3. Gastrosphere yield and drug entrapment efficiency 
The yield of gastrospheres was determined by measuring the dry weight of the formed 
gastrospheres and comparing it to the weight of the initial dry formulation components. 
Drug entrapment efficiency (DEE) studies were performed by stirring ground 
gastrospheres in 100mL phosphate buffer solution (PBS) (pH 7.6, 37°C). Thereafter, 
metformin content was determined in triplicate using ultraviolet spectroscopy (CE 
3021, Cecil Instruments, Cambridge, England) at the wavelength maximum of 241nm. 
The DEE was calculated utilizing Equation 3.1 (Streubel et al., 2002). 
 
D  
             [Equation 3.1] 
 
3.2.2.4. In vitro analysis of the drug release from the Gastrospheres 
Drug release studies were conducted employing the USP 35 apparatus 2 dissolution 
test approach (Erweka DT 700, Heusenstamm, Germany). A modification to the 
approach was made by immersing the samples under a ring-mesh assembly (Pillay 
and Fassihi, 1999) in 900mL simulated gastric fluid (SGF) (pH 1.2, 37°C) at a rotation 
speed of 50rpm. SGF was prepared according to USP 32, 2008. 2g sodium chloride 
(NaCl) was dissolved in 100mL deionized water. 7mL of concentrated HCl was then 
added to the solution to result in a solution pH of 1.2. Samples of 5 mL were removed 
at predetermined time intervals and filtered through a 0.45µm Millipore Millex filter 
(Billerica, Massachusetts, USA). Equal volumes of fresh drug-free SGF were replaced 
in order to maintain sink conditions. Samples were then analyzed with UV 
spectroscopy at 241nm. All experiments were conducted in triplicate.  
 
The release data was subjected to a model-independent analysis known as the time-
point approach. Briefly, the Mean Dissolution Time set at 12 hours (MDT12) for each 
formulation was calculated. The application of the MDT12 approach provided a more 
precise analysis of the metformin release performance for comparison of several 
release data sets. Equation 3.2 was employed in this regard (Hopfenberg and Hsu, 
1978; Pillay and Fassihi, 1999). 
 
                                [Equation 3.2] 
Where Mt is the fraction of dose released in time ti = (ti + ti-1) ∕ 2 and M∞ corresponds to the 
loading dose. 
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3.2.2.5. Analysis of the buoyancy of gastrospheres 
A total number of 50 gastrospheres of each formulation were immersed in 100mL SGF 
(pH 1.2; 37°C) and then placed in an orbital shaking incubator (LM-530-2, MRC 
Laboratory Instruments Ltd., Hahistadrut, Holon, Israel) for 12 hours. Each sample was 
observed at predetermined time intervals while noting the number of spheres that 
were/were not buoyant. All experiments were conducted in triplicate. 
 
3.2.2.6. Determination of the gastroadhesion of spheres 
Gastrospheres were immersed in SGF (pH 1.2, 37°C) for predetermined time periods. 
Adhesion was measured using a texture analyzer (TA.XT.plus, StableMicroSystems, 
Surrey, UK) with a simulated gastric membrane covering both the probe and stage 
platform. Samples were tested using an applied force of 2N, a trigger force of 0.05N 
and a contact period of 15 seconds. Adhesion was determined by measuring the force 
required to separate the gastrosphere from the membrane, termed the detachment 
force. This detachment force was determined in terms of the work of adhesion which 
was obtained by calculating the area under the curve (AUC) of the Force-Distance 
textural profile.  All experiments in this study were conducted in triplicate. 
 
3.2.2.7. Evaluation of the hydration of gastrospheres 
A total number of 50 spheres of each formulation were weighed and immersed in 
100mL SGF (pH 1.2; 37°C) and placed in an orbital shaker incubator for 12 hours. The 
spheres of each formulation were removed at predetermined time intervals, blotted 
with filter paper to remove excess SGF and weighed. All experiments were conducted 
in triplicate. The swelling characteristics of the gastrospheres were expressed in terms 
of water uptake (Chavanpatil et al., 2006) using Equation 3.3. 
 
           [Equation 3.3] 
 
3.2.2.8. Constraint optimization of formulation responses 
A model-independent approach (Minitab® V15, Minitab Inc., Pennsylvania USA) was 
used to optimize the lyophilized gastrospheres. Statistical optimization was therefore 
employed to ascertain the ideal polymeric combination with the desired 
physicochemical properties capable of attaining optimum gastroadhesive strength and 
a predicted MDT12 value which would conform to zero-order kinetics over 12 hours. 
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3.2.2.9. Fourier Transform Infrared analysis 
FTIR spectroscopy was performed on the crosslinked gastrospheres and its 
constituent polymers. Samples were scanned over a wave number range of 4000 to 
650cm−1 using a Perkin Elmer FTIR spectrometer with a MIRTGS detector, 
(PerkinElmer Spectrum 100, Llantrisant, Wales, UK). The spectrum was at a ratio of 
16 sample scans against 16 background scans. Samples were placed on a diamond 
crystal and processed by universal ATR polarization accessory for the FTIR spectrum 
series, at a resolution of 4cm-1. 
 
3.2.2.10. Analysis of surface area and porosity 
Surface area and porosity analysis was conducted using the Micromeritics ASAP 
Analyzer (Micromeritics ASAP 2020, Georgia, USA). Samples were initially subjected 
to degassing to remove surface moisture and gas particles prior to analysis. 
Degassing encompassed an evacuation phase and a heating phase. The respective 
parameters are shown in Table 3.2. 
 
 Table 3.2: Evacuation and heating phase parameters during degassing. 
Parameter Rate/Target 
                         Evacuation Phase 
                         Temperature ramp rate 
 
10°C/min 
                         Target temperature 90°C 
                         Evacuation rate 50.0mmHg/s 
                         Unrestricted evacuation from 30mmHg 
                         Vacuum set point 500µmHg 
                         Evacuation time 60 min 
 
                       Heating Phase 
          Temperature ramp rate 
 
10°C/min 
                       Hold temperature 120°C 
                       Hold time 900 min 
 
Each polymer matrix was weighed and inserted into the sample tube. Subsequently, a 
glass filler rod was inserted into the sample tube to decrease the total free space 
within the tube thus allowing a reduction in the time required for complete degassing to 
occur. The time required for degassing to be completed ranged from 7 to 9 hours. After 
being completely degassed, the sample tube was removed, covered with a thermal 
jacket and transferred to the analysis port where it was cooled with liquid nitrogen prior 
to the analysis. 
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3.2.2.11. Analysis of the surface morphology of the gastrospheres 
Scanning Electron Microscope (SEM) analysis was carried out using a Phenom™ 
scanning electron microscope (FEI Company, OR, USA). Samples were made 
electrically conductive prior to analysis through the process of gold-sputter coating 
(SPI Module™ Sputter Coater, SPI Supplies, PA, USA). 
Samples were attached to an SEM stub using adhesive carbon tape. The stub was 
inserted into the stub holder thereafter putting the glass chamber and sputter head in 
place. Argon gas was allowed to flush the system before the leak valve was sealed 
and the vacuum was turned on. The sputter coater was turned on for 90 seconds when 
plasma current reached 18mA, after which the system was turned off and the vacuum 
released. 
 
3.2.2.12. Molecular mechanics simulations 
Molecular Mechanics Computations in vacuum, which included the model building of 
the energy-minimized structures of multi-polymer complexes, were performed using 
the HyperChemTM 8.0.8 Molecular Modeling System (Hypercube Inc., Gainesville, 
Florida, USA) and ChemBio3D Ultra 11.0 (CambridgeSoft Corporation, Cambridge, 
UK) on an HP Pavilion dv5 Pentium Dual CPU T3200 workstation. The decamers of 
PAA and PLGA were generated as 3D models from standard bond lengths and angles 
employing polymer builder tools using ChemBio3D Ultra in their syndiotactic 
stereochemistry whereas the structures of alginate and pectin (ten oligosaccharide 
units each) were generated using sugar builder module on HyperChem 8.0.8. The 
structure of glycosylated gastric mucopeptide analogue (MUC) was generated on 
sequence editor module on HyperChem 8.0.8. The glycosylation was carried out at the 
threonine and serine amino acid residues. The generation of the overall steric energy 
associated with the energy-minimized structures was initially executed via energy-
minimization using MM+ force field and the resulting structures were again energy-
minimized using the Amber 3 (Assisted Model Building and Energy Refinements) force 
field. The conformer having the lowest energy was used to create the polymer-polymer 
and polymer-mucin complexes. A complex of one molecule with another was 
assembled by disposing them in a parallel way, and the same procedure of energy-
minimization was repeated to generate the final models: ALG-Pec, ALG-Pec-Ca2+, 
ALG-Pec-PAA, ALG-Pec-PAA-Ca2+, ALG-Pec-PAA-PLGA, ALG-Pec-PAA-PLGA-Ca2+, 
MUC-Polymers and MUC-Polymers- Ca2+. Full geometry optimizations were carried 
out in vacuum employing the Polak–Ribiere conjugate gradient method until an RMS 
gradient of 0.001kcal/mol was reached. Force field options in the AMBER (with all 
hydrogen atoms explicitly included) and MM+ (extended to incorporate non-bonded 
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cut-offs and restraints) methods were the HyperChem 8.0.8 defaults. For calculations 
of energy attributes, the force fields were utilized with a distance-dependent dielectric 
constant scaled by a factor of 1. The 1-4 scale factors are the following: electrostatic 
0.5 and van der Waals 0.5. 
 
3.3. RESULTS AND DISCUSSION 
3.3.1. Determination of gastrosphere yield and entrapment efficiency 
Gastrosphere yield values obtained from the 15 formulations ranged between 83 and 
98%, with an average of 93.5%. Figure 3.1 provides the results obtained for each 
formulation. 
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Figure 3.1: Gastrosphere yield of various crosslinked gastrospheres formulated as per 
the statistical experimental design template generated (N=3, SD<9 in all cases). 
 
Entrapment efficiency values of metformin within the crosslinked gastrospheres ranged 
from 18 to 54%. Figure 3.2 provides the drug entrapment efficacy values obtained for 
each formulation. The rather low entrapment efficiency values are due to drug loss 
during the crosslinking step, which is exacerbated due to the high water solubility of 
metformin.  
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Figure 3.2: Drug entrapment efficiency of metformin within various crosslinked 
gastrospheres formulated as per the statistical experimental design template 
generated (N=3, SD<13 in all cases). 
 
3.3.2. In vitro drug release from the Gastrospheres 
 Due to the intended purpose of this drug delivery system, zero-order drug release is 
the ideal drug release pattern. Three profiles of drug release were achieved, namely 
near zero-order release, first order release and burst release. 
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Figure 3.3: Drug release profiles. a) Pseudo zero-order drug release; b) First-order 
drug release; and c) Burst release of metformin from gastrospheres in SHGF (pH 1.2; 
37°C) (N=3, SD≤0.075 in all cases). 
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Figure 3.3(a) shows that formulations 3, 11 and 13 displayed pseudo zero-order drug 
release over the 12 hour period, resulting in 85%, 75% and 60% final drug release 
respectively. In order to achieve a constant plasma metformin concentration over the 
entire 12 hour period and to avoid peaks and troughs which are commonly associated 
with side effects, zero order release is ideal.  
 
First-order drug release was observed from formulations 4 and 9, with 80% and 66% 
final drug release as shown in Figure 3.3(b). Formulations 5, 8 and 12 (Figure 3.3c), 
displayed an initial burst release, followed by a zero-order release. More than 50% of 
the final drug concentration was released within the first hour, followed by a gradual 
zero-order release over the subsequent 11 hours. Although not ideal for our 
application, this profile may be appropriate for systems which may require a high 
loading dose and subsequent maintenance of plasma concentration. 
 
In order to evaluate drug release, Mean Dissolution Time after 12 hours (MDT12) was 
employed. The application of the MDT12 approach provides a more precise analysis of 
the metformin release performance for comparison of several release data sets. 
 
3.3.3. Analysis of gastrosphere buoyancy 
Excellent in vitro buoyancy was observed for all 15 formulations. The gastrospheres 
were immediately buoyant on contact with the SGF. Data obtained revealed that 
99.0% of gastrospheres were buoyant after 8 hours. Buoyancy is slightly reduced to 
97.5% after the full 12 hour period, although this reduction appears totally insignificant. 
The buoyancy of this system can be attributed to the low apparent density of the 
gastrospheres, resulting from the highly porous structure attained from the 
lyophilization process. 
 
3.3.4. Determination of the gastroadhesive strength 
Gastroadhesion was found to be greatly variable between formulations due to the high 
sensitivity of PAA compared to other polymers. PLGA, due to its hydrophobic nature, 
inhibited the absorption of water, whereas PAA being hydrophilic resulted into the 
attraction of water molecules. The results indicated that both high PAA and PLGA 
concentrations were required for two distinctive purposes; PAA being highly 
bioadhesive maintained proper gastroadhesivity while PLGA inhibited the water uptake 
(by virtue of its hydrophobicity)  so as to give room for PAA to facilitate adhesion over 
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the 12 hour period. The concentrations of pectin and alginate also played a significant 
role in facilitating the adhesion. 
 
It was decided that two factors relating to mucoadhesion had to be taken into account 
when analysing the results. The area under the curve (AUC) of each formulation was 
calculated in order to analyse the data (i.e. to obtain the work of adhesion) as 
illustrated in Figure 3.4. In order to prevent an immediate passage of the 
gastrospheres from the stomach, the AUC from time 0 to 2 hours (T0-2) was calculated 
as the first factor. The second factor was determined by calculating the AUC from time 
2 to 12 hours (T2-12), representing the ability to maintain adhesion throughout the full 
12 hours. The optimum formulation must possess the greatest of both factors.                  
AUC = Force of detachment
Figure 3.4: A typical textural profile illustrating the calculated area under the curve 
(AUC). 
 
3.3.5. Calculation of water uptake and the swelling tendency of the 
gastrospheres 
The degree of swelling for the polymers used has been determined by the water 
uptake capacity of the gastrospheres. Although the drug delivery system is intended as 
a twice daily dosage regime, it was found that optimal water uptake occurred at 8 
hours, after which, there was a slight reduction in water uptake. Figure 3.5 depicts the 
effects that each polymer had on the swelling ability of the drug delivery system. It was 
evident that an increase in PLGA resulted in a reduction of swelling. This was most 
probably due to the hydrophobic nature of the polymer, reducing the overall attraction 
of water to the gastrospheres. Pectin and sodium alginate had a similar effect, where 
the degree of swelling was reduced with increasing concentrations. However, due the 
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high hydrophilic and bioadhesive nature of PAA, water molecules were strongly 
attracted to the gastrospheres, thus resulting in an increase in swelling with an 
increasing concentration. 
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Figure 3.5: Effect of various polymeric concentrations on swelling after 8 hours (N=3, 
SD<32 in all cases). 
 
3.3.6. Response surface analysis 
Response surface plots (Figures 3.7, 3.8 and 3.9) were obtained for the measured 
responses (MDT12, T0-2, T2-12) based on the experimental model, representing the 
functional relationship between the response and the experimental factors. 
 
3.3.6.1. Analysis of the Box-Behnken response surface design  
MDT12, T0-2 and T2-12 for the experimental formulations were included in the statistical 
design for the identification of the formulation possessing optimum drug release and 
gastroadhesion. Residual analysis for MDT12, T0-2 and T2-12 (Figures 3.6a, b and c 
respectively) generally showed random scatter, indicating that no trends were present; 
however, some grouping was observed for T0-2. The normal probability plots of the 
residuals fell on a straight line, thus indicating that the data was normally distributed 
and there was a non-existence of unidentified variables. 
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Figure 3.6: Residual Plots for: a) MDT12; b) T0-2; and c) T2-12. 
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The complete regression equations generated for MDT12, T0-2 and T2-12 are indicated 
below:  
 
MDT12 = 47.1094 - 12.5160[ALG]-5.94507[PAA] + 0.679866[PLGA] + 
3.59370[ALG*ALG] + 1.19402[PAA*PAA] + 0.452163[PLGA*PLGA] + 
1.30763[ALG*PAA] - 0.513957[ALG*PLGA] - 0.377558[PAA*PLGA] 
[Equation 3.4] 
 
T0-2 = 0.323909 - 0.248121[ALG] - 0.0509750[PAA] - 0.0225549[PLGA] + 
0.0524639[ALG*ALG] - 0.0116194[PAA*PAA] + 0.000949306[PLGA*PLGA] + 
0.0428333[ALG*PAA] - 0.0241250 [ALG*PLGA] + 0.0355833[PAA*PLGA]      
[Equation 3.5] 
 
T2-12 = -0.0499556 - 0.130288[ALG] + 0.267579[PAA] + 0.0134806[PLGA] + 
0.0669556[ALG*ALG] - 0.0580778[PAA*PAA] + 0.0142681[PLGA*PLGA] - 
0.0273333[ALG*PAA] - 0.0603417[ALG*PLGA] + 0.0301417[PAA*PLGA] 
[Equation 3.6] 
 
3.3.6.2. Response surface analysis for Mean Dissolution Time  
The effect of factors ALG/PEC and PAA at the midpoint of factor PLGA on response 
MDT12 is shown in Figure 3.7(a). At low levels of factor PAA, MDT12 was high and 
increasing the factor ALG/PEC from 1 to 1.5% resulted in a reduction of MDT12, 
although as the factor was further increased from 1.5 to 2%, an increase in MDT was 
noted. At high levels of factor ALG/PEC, MDT12 was moderate. An initial increase in 
factor PAA from 1 to 1.5% resulted in a reduction of MDT12, although further increasing 
the level of factor PAA from 1.5 to 2% resulted in the return of MDT12 to its original 
value. 
 
The effect of factors PAA and PLGA at the midpoint of factor ALG/PEC on response 
MDT12 is shown in Figure 3.7(b). At low levels of PAA, MDT12 was moderate, 
increasing with an increase in factor PLGA. At high levels of PAA, MDT12 was low, 
reducing as PLGA was increased from 0 to 1%, and returning to the original value as 
PLGA was further increased to 2%.  
 
The effect of factors ALG/PEC and PLGA at the midpoint of factor PAA on response 
MDT12 is shown in Figure 3.7(c). At low levels of ALG/PEC, MDT12 was moderate; 
increasing as factor PLGA was increased. At high values of factor ALG/PLGA, an 
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increase in factor PLGA from 0 to 1% resulted in a reduction of MDT12, although 
increasing this factor further to 2% reulted in an increase of MDT, returning to its 
orignal value.  
 
The effect of PLGA may be explained due to the fact that it is a lypophilic polymer 
which does not rapidly degrade or swell, obstructing the release of drug from the 
gastrospheres, thereby prolonging drug release. 
 
Figure 3.7: Response surface plots generated for MDT12. 
 
3.3.6.3. Response surface analysis for mucoadhesion from 0 to 2 hours 
The effect of factors ALG/PEC and PAA at the midpoint of factor PLGA on response 
T0-2 is shown in Figure 3.8(a). At low levels of factor ALG/PEC, T0-2 was high. 
Increasing the level of factor PAA resulted in a slight reduction of T0-2. At high levels of 
ALG/PEC, was T0-2 low, increasing with an increase in PAA. 
 
The effect of factors PAA and PLGA at the midpoint of factor ALG/PEC on response 
T0-2 is shown in Figure 3.8(b). At low levels of PAA, T0-2 was high; decreasing as the 
level of factor PLGA was increased. However, T0-2 was low at high levels of PAA, 
increasing with an increase in the level of PLGA.  
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The effect of factors ALG/PEC and PLGA at the midpoint of factor PAA on response 
T0-2 is shown in Figure 3.8(c). At low levels of PLGA and ALG/PEC, T0-2 was high, 
decreasing with an increase in the level of ALG/PEC. At low levels of ALG/PEC, T0-2 
was moderate, increasing as the level of PLGA increased, although at high levels of 
ALG/PEC, T0-2 decreased as the level of PLGA increased. 
 
Figure 3.8: Response surface plots generated for T0-2. 
 
3.3.6.4. Response Surface Analysis for Mucoadhesion from 2 to 12 hours 
The effect of factors ALG/PEC and PAA at the midpoint of factor PLGA on response 
T2-12 is shown in Figure 3.9(a). At low levels of factor ALG/PEC, T2-12 was low, 
increasing with an increase in factor PAA. At high levels of ALG/PEC, T2-12 was also 
low and an increase in the levels of PAA had the same effect, although to a lesser 
degree. 
 
The effect of factors PAA and PLGA at the midpoint of factor ALG/PEC on response 
T2-12 is shown in Figure 3.9(b). At low levels of factor PAA, T2-12 was low and was 
further reduced as the level of factor PLGA increased. At high levels of PAA, T2-12 was 
high, although a reduction in T2-12 was noted as the level of factor PLGA increased 
from 0 to 1%, followed by a subsequent increase as levels reached 2%. 
 
The effect of factors ALG/PEC and PLGA at the midpoint of factor PAA on response 
T2-12 is shown in Figure 3.9(c). At low levels of ALG/PEC, T2-12 was moderate, 
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increasing as the level of PLGA increased. At high levels of ALG/PEC, T2-12 was 
increased slightly, although a reduction of T2-12 was observed with an increase in the 
level of factor PLGA. 
 
 
Figure 3.9: Response surface plots generated for T2-12. 
 
3.3.7. Constraint optimization of formulation responses for the crosslinked 
gastrospheres 
Minitab® V15 (Minitab Inc., California, USA) was used to optimize the formulation 
responses namely, the MDT12, strength of adhesion after 2 hours (T0-2) and strength of 
adhesion from 2 to 12 hours (T2-12).  These responses were selected due to the 
fundamental role they provide for the qualitative modeling of metformin release from 
the crosslinked gastrospheres. Optimal responses generated by the inherent 
optimization function of Minitab® are represented by the desirability plots in Figure 
3.10. MDT12 was computed to converge to zero-order kinetics of metformin release 
from the optimized gastrosphere formulation. T0-2 and T2-12 were computed in a manner 
that would permit maximum gastroadhesion for both. The constraints that were 
imposed in order to achieve the desired responses are listed in Table 3.3. According to 
the predictions of the statistical design, the optimal gastrosphere that would permit a 
desirable MDT12 value of 34.833 (which is reflective of zero-order kinetics over 12 
hours) and the greatest strength of adhesion for both the first 2 hours as well as the 
subsequent 10 hours would result in two possible formulations (Table 3.4). 
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Table 3.3: Formulation constraints employed for response optimization. 
Variables Limits 
Alginate/Pectin 1-2% w/v 
PAA 1-2% w/v 
PLGA 0-2% w/v 
 
MDT12 
 
34.883 
T0-2 Maximum 
T2-12 Maximum 
 
 
Table 3.4: Predicted optimized formulations obtained via the surface response 
method. 
Gastrosphere 
Formulations 
[Alginate] 
(%) 
[Pectin] 
(%) 
[PAA] 
(%) 
[PLGA] 
(%) 
1 1 1 2 2 
2 1 1 1.478 0 
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Figure 3.10: Optimization plots delineating factor settings and desirability values for 
optimal formulations: (a) F1; and (b) F2. 
 
Drug release data obtained for the two optimized formulations are shown in Figure 
3.11. It can be observed that the first formulation displayed a more preferable profile 
due to the higher final drug release of 92% as compared to the 63% obtained from the 
second formulation (Figure 3.11). 
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Figure 3.11: Fractional drug release obtained from the two optimized formulations 
(N=3, SD<0.12 in all cases). 
 
From Figure 3.12 it is evident that F1 possesses a much greater strength of adhesion 
after both t0-2 and t2-12 when compared with F2. 
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Figure 3.12: Strength of adhesion of the two optimization formulations (N=3, 
SD<0.003 in all cases). 
 
3.3.7.1. Experimental and predicted response values for the optimized 
formulations 
Both ideal formulations were prepared in accordance with the optimal predicted 
settings. The experimentally derived values for the MDT12, T0-2 and T2-12 of formulation 
F1 were in close agreement with the predicted values (Table 3.5), and is obviously a 
far superior formulation in comparison to formulation F2. 
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Table 3.5: Experimental and predicted response values for the optimized formulations. 
Measured 
Response 
Formulation Predicted 
Response 
Actual 
Response 
Desirability 
MDT12 F1 33.9459 32.3367 0.78919 
 F2 34.3185 33.81803 0.86370 
T0-2 F1 0.0910 0.0723 0.82031 
 F2 0.1183 0.0436 1.00000 
T2-12 F1 0.1146 0.0985 1.00000 
 F2 0.2188 0.0297 1.00000 
 
3.3.8. Characterisation of the gastrospheres by Fourier-Transform Infrared 
Spectroscopy  
Figure 3.13 shows the FTIR spectra of each component polymer as well as that of the 
crosslinked gastrosphere. It is evident that most of the strong bonds belonging to 
PLGA and PAA are still present, although to a lesser degree. These bonds include O-
H stretching vibration (2500-3600cm-1), ester bonds (1600-1800cm-1), C=O stretching 
vibrations (1590–1750cm-1) and C-O-C vibrations (1000-1200cm-1). Notably, there was 
no overlapping tendency that featured between the wave bands of the native polymers 
and that of gastrospheres (Figure 3.13) indicating that there was no interaction 
between the drug and the polymers employed in the formulations. 
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Figure 3.13: FTIR spectra of the component polymers and the crosslinked 
gastrospheres. 
 
3.3.9. Analysis of surface area and porosity 
A comparison was made between a sample of gastrospheres which were lyophilized 
and a sample which was air dried. The results of BET surface analysis are shown in 
Figure 3.14. It could be visually elucidated that the air dried sample was significantly 
smaller than the lyophilized sample due to structural collapse during the drying 
process. This was confirmed by the results obtained from the surface area analysis, 
which revealed that surface area and pore volume were reduced by 82.3% and 39.3% 
respectively with the exclusion of the lyophilization process. These results assist in 
emphasizing the importance of the lyophilization process in the development of a low 
density gastrospheres, and therefore buoyant, system. 
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BET Surface Area:    0.9970 ± 0.0275 m²/g 
Slope:    4.158030 ± 0.119348 g/cm³ STP
Y-Intercept:    0.208290 ± 0.016544 g/cm³ STP
C:    20.962725 
Qm:    0.2290 cm³/g STP 
Correlation Coefficient:    0.9975375 
Molecular Cross-Sectional Area:    0.1620 nm² 
BET Surface Area:    0.2222 ± 0.0114 m²/g 
Slope:    18.113284 ± 0.994725 g/cm³ STP
Y-Intercept:    1.477876 ± 0.137926 g/cm³ STP
C:    13.256296
Qm:    0.0510 cm³/g STP
Correlation Coefficient:    0.9910734 
Molecular Cross-Sectional Area:    0.1620 nm² 
a) b)
 
Figure 3.14: BET surface analysis. a) lyophilized; and b) air-dried gastrospheres. 
 
3.3.10. Surface characterisation of the gastrospheres 
Figure 3.15 shows an SEM image of a gastrosphere at a magnification of 440x. It was 
observed that the entire surface of the gastrosphere was covered with air pockets just 
below the surface. When these air pockets formed too near the surface, they ruptured, 
resulting in the formation of pores and channels. The presence of these air pockets 
visually confirms the presence of pores within the gastrosphere which are responsible 
for its low density and resultant buoyancy. 
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Figure 3.15: Typical SEM image of the surface of a gastrosphere at a magnification of 
440x. 
 
3.3.11. Molecular mechanics elucidation of the performance of gastrosphere 
drug delivery system 
The present communication dealt with the fabrication of a drug delivery system 
integrating a unique combination of polymers with acidic functionalities such as 
alginate (mannuronic and guluronic acid residues), pectin (galacturonic acid residues), 
PAA and PLGA (polyhydroxy acid derivative of lactic and glycolic acid). Among these 
polymers, all except PLGA are known to exhibit interactions with divalent cations such 
as Ca2+ where alginate and pectin display crosslinking with Ca2+ ions (da Silva et al., 
2009) and polyacrylic acid exhibit complexation of calcium ions (Kriwet and Kissel, 
1996). It is evident from Table 3.6 that ALG-Ca2+ is energetically stabilized by 37 
kcal/mol as compared to ALG because of strong electrostatic interactions along with 
high torsional energy (Figure 3.16a). However, in case of Pec-Ca2+, the energy of 
interaction is about 9 kcal/mol mainly arising due to van der Waals forces. This 
somewhat hydrophobic stabilization was probably due to the presence of methyl 
groups (as methyl esters) in pectin structure. Furthermore, the ALG-Pec complex is 
destabilized by 13 kcal/mol demonstrating the necessity of crosslinking the bipolymeric 
structure with Ca2+ ions which was confirmed by the high degree of conformational 
stability (42 kcal/mol) in ALG-Pec-Ca2+. In addition, the crosslinked structures was 
more closely packed displaying the spatial preference of the polymeric chains in 
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response to the presence of Ca2+ (Figure 3.16 a, c and d). Both ALG-Pec and ALG-
Pec-Ca2+ displayed intra- and inter-polymeric hydrogen bonding, although at different 
positions, as depicted in Figure 3.16. These results are in line with the earlier reported 
studies where the polyguluronates (alginate) displayed better strength and the 
stereospecificity in binding to Ca2+ through “Egg-box model” as compared to 
polygalacturonates (pectin) (Braccini and Pe´rez, 2001). 
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Table 3.6: Calculated energy parameters (kcal/mol) of the polymer-polymer and polymer-protein assemblies complexes ALG, Pec, 
PAA, PLGA and gylcosylated MUC. 
Structure 
Energy (kcal/mol) 
Totala ΔEb Bondc Angled Dihedrale VDW
f H bondg Elec
h 
ALG 74.426 - 5.204 32.485 34.108 30.709 0 -28.142 
ALG Ca2+ 36.548 -37.452 5.502 30.586 40.364 35.197 0 -75.102 
Pec -68.280 - 5.231 50.779 59.971 15.331 -8.022 -191.564 
Pec Ca2+ -76.894 -8.614 5.194 50.977 60.072 6.704 -8.024 -191.817 
ALG-Pec 19.509 13.363 10.923 85.783 97.369 26.523 -8.034 -193.054 
ALG-Pec Ca2+ -22.862 -42.371 11.215 84.019 100.076 32.13 -8.699 -241.603 
PAA 10.258 - 1.517 7.178 4.244 -2.540 -0.142 0 
PAA Ca2+ 1.597 -8.661 1.504 7.202 4.151 -11.117 -0.143 0 
ALG-Pec-PAA 2.167 -17.342 13.099 98.079 104.553 -8.058 -9.624 -195.883 
ALG-Pec-PAA Ca2+ -48.238 -50.405 13.124 96.918 104.16 -11.512 -11.336 -239.593 
PLGA 3.941 - 0.423 3.764 1.789 -2.028 -0.007 0 
ALG-Pec-PAA-PLGA -48.608 -54.346 13.786 109.649 106.446 -63.481 -9.367 -205.64 
ALG-Pec-PAA-PLGA Ca2+ -85.372 -36.764 13.326 100.403 108.598 -58.105 -12.569 -237.027 
GlycoMucin -166.812 - 5.474 70.351 55.173 -29.066 -7.096 -261.649 
GlycoMucin-Polymers -315.117 -99.697 20.078 187.27 189.902 -114.094 -23.812 -574.47 
GlycoMucin-Polymers Ca2+ -255.515 -3.331 19.762 205.956 179.337 -116.819 -18.079 -525.673 
a Total steric energy for an optimized structure 
b ΔEinteraction = E(Host:Guest) - E(Host) - E(Guest) 
c Bond stretching contributions, reference values were assigned to all of a structure's bond lengths 
d Bond angle contributions, reference values were assigned to all of a structure's bond angles 
e Torsional contribution arising from deviations from optimum dihedral angles 
f van der Waals interactions due to non-bonded interatomic distances 
g Hydrogen-bond energy function 
h Electrostatic energy 
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Figure 3.16: Energy minimized constrained models of the polymeric assemblies 
derived from molecular mechanics calculations. (a) Alginate-Ca2+; (b) Pectin-Ca2+; (c) 
Alginate-Pectin; and (d) Alginate-Pectin-Ca2+. Colour codes for elements are: Carbon 
(cyan); Hydrogen (white-tubes); Oxygen (red); and Nitrogen (blue). Calcium ions are 
rendered spherically in white. 
 
Likewise pectin, PAA-Ca2+ also displayed a rather small energy of interaction as 
compared to alginate and was stabilized mainly by the van der Waals forces owing to 
the presence of methyl groups in the structure of PAA. The addition of PAA to ALG-
Pec, further stabilized the polymeric structure by 17 kcal/mol instituted by all the non-
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bonding interactions viz., van der Waals forces, H-bonding and electrostatic 
interactions (Table 3.6). These non-bonding interactions also contributed to the energy 
minimization of spatially constrained geometrical model of ALG-Pec-PAA-Ca2+ (Figure 
3.17a and b). It is noteworthy that the addition of PAA to ALG-Pec increased the inter-
polymeric hydrogen bonding between alginate and pectin and the addition of Ca2+ to 
ALG-Pec-PAA increased the structural integrity of the tripolymer complex as 
represented in Figure 3.17. The formation of H-bonding between PAA and alginate 
and PAA and Pectin can also be seen in Figure 3.17 confirming the rationality of 
incorporating PAA in to the alginate-pectin platform.  
 
As expected, PLGA, a hydrophobic polymer, when added to the tripolymer complex 
displayed a very high energy of interaction (ΔE=-54.346kcal/mol) attributable to very 
high van der Waals interactions primarily due to non-bonded interatomic distances. 
Surprisingly, the total steric energy of this quad-polymer was almost equal to the Ca2+ 
crosslinked ALG-Pec-PAA and the ΔE of formation of both was also similar. However, 
the structural integrity in terms of closed packing was still a concern. The incorporation 
of Ca2+ to this quad-polymer decreased the bond angle contributions resulting in a 
more sterically constrained structure which was also responsible for the not so high ΔE 
in case of ALG-Pec-PAA-PLGA Ca2+. 
 
The aforementioned in silico results corroborated with the experimental in vitro drug 
release profiles in terms of MDT12. The MDT12 decreased, and hence the rate of drug 
release increased, with an increase in ALG/PEC and PAA levels from 1 to 1.5% at low 
and high levels of PAA and ALG/PEC, respectively. This increase in drug release with 
an increase in ALG/PEC and PAA may be due to the hydrophilic nature and hence 
increased swelling of the polymers leading to enhanced diffusion of the drug. 
Furthermore, an increase in polymer level, decrease the Ca2+ ions available per 
polymeric fragment resulting in a decrease in crosslinking and hence rigidity of the 
matrix (Figure 3.17). However, a further increase in polymer levels from 1.5 to 2% 
increased the MDT12 and hence decreased the drug release. This may be attributed to 
the fact that with an increase in level of polymers, the polymer density increases and 
the space available for swelling decreases thereby decreasing the diffusion of the drug 
from the polymer matrix (Figure 3.17). Furthermore, the increase in polymer density 
may have facilitated the Ca2+ to form all the possible associations with the ordered 
polyguluronate and polygalacturonate chains to form dimers resulting in a highly 
crosslinked polymeric framework (Figure 3.17) (Braccini and Pe´rez, 2001). The 
increase in MDT12 with an increase in PLGA was obvious due to the fact that PLGA is 
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hydrophobic and even energetically produced an effect similar to Ca2+ as described in 
the previous paragraph. 
 
 
Figure 3.17: Energy minimized geometrical preferences of the multi-polymeric 
polyelectrolyte complexes derived from molecular mechanics calculations. (a) 
Alginate-PAA-Pectin; (b) Alginate-PAA-Pectin-Ca2+; (c) Alginate-PAA-Pectin-PLGA; 
and (d) Alginate-PAA-Pectin-PLGA-Ca2+.  Colour codes for polymer chains are: 
Alginate (red); PAA (violet); Pectin (yellow); and PLGA (green). Calcium ions are 
rendered spherically in white. 
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The bioadhesive or mucoadhesive potential of the multiparticulate delivery system was 
elucidated as being a measure of specific chemical interactions between the polymeric 
matrix (ALG-Pec-PAA-PLGA) or the Ca2+-crosslinked polymeric matrix (ALG-Pec-PAA-
PLGA Ca2+) and the glycosylated gastric mucopeptide analogue (MUC) after 
geometrical optimization using energy minimizations. The stress transduction for 
energy minimization was found to be a collective phenomenon including interactions in 
the form of van der Waals forces, H-bonding and electrostatic interactions contributing 
to the binding energy (Table 3.6) while requiring a large fraction of the surface to 
establish connectivity between chemically transformed regions. The binding energy of 
the polymer matrix with MUC was quite high reaching up to 100 kcal/mol confirming 
the significant interaction between the two (Figure 3.18; Table 3.6). However, the 
minimized energy increased significantly after introducing the Ca2+ ions in the MUC-
polymer system leading to a comparatively destabilized conformation. Additionally, the 
H-bonds formed between the polymer matrix and the MUC were lessened in case of 
Ca2+-crosslinked system. A deeper inspection of the MUC-polymer shows that the 
specificity of this complex arises due to hydrophobic interactions of the methyl groups 
of the mucopeptide residues with oxygen atoms of the polymers. Furthermore, the 
binding was more pronounced with PAA and the polysaccharide chains, preferably the 
alginate, as depicted in Figure 3.18. The inherent mechanism involved in the reduction 
and stabilization of Ca2+-crosslinked matrix may be attributed to the formation of a 
strained network structure due to calcium crosslinking thereby limiting the complete 
interaction as observed with the non-crosslinked structure (Figure 3.18). 
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Figure 3.18: The chemical and geometrical binding interactions involving polymers 
and the glycosylated gastric mucopeptide analogue. (a) GlycoMucin-Polymers; and (b) 
GlycoMucin-Polymers-Ca2+. Polymers are depicted in tube rendering and MUC is 
depicted in stick rendering. Colour codes for elements are: Carbon (cyan); Nitrogen 
(blue); Oxygen (red); and Hydrogen (white-stick). Colour codes for polymer chains are: 
Alginate (red); PAA (violet); Pectin (yellow); and PLGA (green). Calcium ions are 
rendered spherically in white. 
 
The experimental mucoadhesion studies can also be correlated to these in silico 
findings. Like MDT12 studies, mucoadhesion was also characterized by a "region of 
maximum" whereby the gastro-adhesion was dependent on the swelling extent of the 
polymeric matrix. As described earlier in this chapter, an optimum swelling was 
required for an effective bioadhesion. The 3-D plot depicted an initial increase in 
mucoadhesion with increase in the amount of polymers up to the intermediate levels 
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and decreased thereafter. Maximum mucoadhesion, therefore, was seen at the 
intermediate level of the polymer ratio. It may be because of the fact that the hydrogels 
swell readily (with higher amount of PAA), when they come in contact with hydrated 
mucous membrane and hydrogels become progressively elastic due to uncoiling of 
polymer chains and subsequent increased mobility of the polymer chains resulting in a 
large adhesive surface for maximum contact with mucosa and flexibility to the polymer 
chains for interpenetration with mucosa (Kumar and Bhatia, 2010). Increasing the 
alginate, pectin and PAA amount may provide more adhesive sites and polymer chains 
for interpenetration with mucosa, resulting consequently in the augmentation of 
mucoadhesive strength. On the other hand, a further increase in the amount of these 
hydrophilic polymers may render the network structure too loose to hold the tethered 
mucous chains thereby decreasing the mucoadhesion (Kumar and Bhatia, 2010). 
PLGA appeared to play its role here in sustaining the matrix integrity by controlling the 
swelling of the matrix and hence the mucoadhesion. 
 
3.4. CONCLUDING REMARKS 
A randomized Box-Behnken statistical experimental design was utilised in order to 
develop and optimize a novel approach for the formulation of gastrospheres intended 
for the delivery of narrow absorption window drugs. A range of formulations varying in 
release characteristics and gastroadhesion, where obtained. Response surface design 
was employed in order to identify the relationships between the responses (MDT12, T0-2 
and T2-12) and the experimental factors (ALG/PEC, PAA and PLGA). Optimization of 
experimental factors resulted in the generation of an optimal formulation possessing 
maximal gastroadhesion over the entire 12 hour period as well as an MDT12 of 32.33, 
which is capable of displaying a zero-order rate of drug release. The molecular 
mechanics (MM) simulations ascertained that the in silico results corroborated well 
with the experimentally obtained in vitro drug release profiles. Furthermore, the 
bioadhesive or mucoadhesive potential of the multiparticulate delivery system was 
elucidated via MM simulations as being a measure of specific chemical interactions 
between the polymeric matrix (ALG-Pec-PAA-PLGA) or the Ca2+-crosslinked polymeric 
matrix (ALG-Pec-PAA-PLGA Ca2+) and the glycosylated gastric mucopeptide analogue 
after geometrical optimization using energy minimizations. Thus, stress transduction 
for energy minimization was found to be a collective phenomenon including 
interactions in the form of van der Waals forces, H-bonding and electrostatic 
interactions contributing to the binding energy. The results obtained give much 
promise that the developed drug delivery system may find a good application in the 
delivery of narrow absorption window drugs. 
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CHAPTER 4 
Development, Design and Optimization of Microparticle-Loaded Gastrospheres 
 
4.1. INTRODUCTION 
Ciprofloxacin is a broad spectrum, second generation fluoroquinolone antibiotic, active 
against both gram-positive and gram-negative bacteria, as well as other micro-
organisms (Zhanel et al., 2002; Imre et al., 2003; Ge, et al., 2009). Ciprofloxacin 
hydrochloride is characterised by a short elimination half-life of 4 hours, high water 
solubility, as well as having a narrow absorption window, mainly being absorbed in the 
duodenum (Tadros, 2009). 
 
Chitosan is a natural cationic polysaccharide that is obtained from the deacetylation of 
chitin which is similar in structure to cellulose (Agnihotri et al., 2004; Ko et al., 2002). 
The presence of primary amine groups gives chitosan special properties which have 
resulted in its extensive use in drug delivery systems (Agnihotri et al., 2004; Dodane 
and Vilivalam, 1998; Felt et al., 1998; Kas, 1997). In order to control the rate at which 
drug is released from a drug delivery system, chitosan can be crosslinked using 
chemical crosslinking agents such as glutaraldehyde (Jameela and Jayakrishnan, 
1995; Blanco et al., 2000), NaOH (Chandy and Sharma, 1996; Lim et al., 1997; 
Vasudev et al., 1997), ethylene glycol diglycidyl ether (Mi et al., 1999) or using an ionic 
crosslinker such as tripolyphosphate (TPP) (Shiraishi et al., 1993; Calvo et al., 1997). 
However, ionic crosslinking is preferable due to the absence of undesirable effects 
such as irritation and toxicity associated with chemical crosslinkers (Lim et al., 1997; 
Shu and Zhu, 2001). TPP is a nontoxic multivalent anion which forms a gel through the 
interaction with the positively charged amino groups of chitosan (Aral and Akbuğa, 
1998; Shu and Zhu, 2001). Chitosan has many advantages for use in drug delivery 
systems. These include biocompatibility and biodegradation, the ability to control the 
rate of drug release, presence of free amine groups that are available for crosslinking, 
its cationic in nature (which allows for ionic crosslinking with multivalent anions), the 
antacid and antiulcer properties (which reduces drug irritation on the stomach) and its 
mucoadhesive nature (Agnihotri et al., 2004, Berscht et al., 1994).  
 
Eudragit® is the trade name for a range of copolymers derived from esters of 
methacrylic and acrylic acid. Water permeability and pH-dependent solubility is 
dependant of the type and frequency of ester substituent’s present (Lin et al., 1994). 
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Due to the broad spectrum of physicochemical properties inherent to the range of 
Eudragit® polymers, they have been used extensively in the production of 
pharmaceutical formulations. Their use varies from film coating and enteric coating to 
the control of the rate of drug release and taste masking (Lin et al., 1990, 1991, 1994). 
Eudragit® polymers are categorised according to their ionic nature, pH dependence 
and solubility (Table 4.1). 
 
Table 4.1: Properties of Eudragit® polymers 
 Ionic 
Nature 
pH dependence Solubility Permeability & 
Swelling 
Eudragit® S 100 Anionic Dissolves at pH 7.0 Methanol, ethanol, 
isopropyl alcohol, 
acetone, 
- 
Eudragit® L 100 Anionic Dissolves at pH 6.0  
Eudragit® E 100 Cationic Dissolves at pH 1.2-
6.0 
As above as well 
as methylene 
chloride, ethyl 
acetate 
- 
Eudragit® RS 100 Cationic Independent Low 
Eudragit® RL 100 Cationic Independent High 
 
The purpose of this chapter was to develop and carry out an in vitro evaluation on 
microparticles, formulated through ionic crosslinking of chitosan and Eudragit® RL 100 
30D that were incorporated into an ionic crosslinked gastrosphere (developed in 
Chapter 3), for the controlled release of ciprofloxacin over a period of 12 hours in a 
zero-order fashion. Chemometric modelling was employed to corroborate the 
experimental findings. 
 
4.2. MATERIALS AND METHODS 
4.2.1. Materials 
The following materials are all of analytical grade and were obtained from commercial 
suppliers and used without further purification. Chitosan (medium molecular weight), 
ciprofloxacin and sodium tripolyphosphate (TPP) were purchased from Sigma-Aldrich 
(Sigma-Aldrich Chemie, Steinheim, Germany), alginate (Protanal LF 10/60, FMC 
BioPolymer, Drammen, Norway), pectin (Classic CU 701, Herbstreith and Fox, 
Neuenbürg, Germany), polyacrylic acid (Carbopol 974P NF, Noveon, Ohio, USA), 
poly(lactic-co-glycolic) acid (Resomer RG 858 S) (Boehringer Ingelheim, Ingelheim, 
Germany) and calcium hydroxide (BDH Chemicals Ltd., Poole, England). Eudragit® RL 
100 30D was received from Röhm Pharma Polymers (Darmstadt, Germany). All other 
reagents used were of analytical grade and were employed as purchased. 
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4.2.2. Methods 
4.2.2.1. Construction of a Face-Centered Central Composite Design 
A central composite design was constructed in order to provide information regarding 
the direct additive effects of the study variables on the physicochemical and 
physicomechanical properties, as well as the pair-wise interaction effects. 
Experimental trials were performed on 14 statistically derived formulations of various 
combinations of polymers. Chitosan (0.5 – 1.5%w/v) and Eudragit® RL100 30D (0.5-
2%w/v) were selected as the independent formulation variables. Mean Dissolution Time 
(MDT12) over 12 hours drug entrapment efficiency and microparticle yield were 
selected as the formulation responses. A statistical model incorporating interactive and 
polynomial terms was utilized to evaluate the responses. Response surface plots were 
constructed to visually represent the influence of the polymeric concentrations on the 
ciprofloxacin release dynamics from the microparticle-loaded gastrospheres. 
 
4.2.2.2. Preparation of microparticles 
A homogenous solution of chitosan, ciprofloxacin and Eudragit® RL 100 30D was 
prepared and aerosolized into a vessel containing 6% w/v TPP under constant rotation. 
Chitosan was dissolved in 1%v/v acetic acid and Eudragit® was dispersed in distilled 
water. Aerosolization was achieved by spraying the polymeric solution through the 
nozzle of a fluid bed drier (Mini Lab Coater, Umang Pharmatech, Maharashtra, India) 
at a constant rate of 5mL/min. The nozzle was kept at a height of 20cm above the 
collection vessel and the air pressure was maintained at 0.1MPa. The microparticles 
were allowed to cure for 30 minutes, after which they were collected via centrifugation, 
washed, frozen at -72°C and lyophilized at -60°C and 25mmtor.  
 
4.2.2.3. Loading of microparticles into gastrospheres 
An aqueous solution consisting of 1% w/v alginate, 1% w/v pectin and 2% w/v PAA was 
prepared, and PLGA (2%w/v) was dissolved in dichloromethane.  Both polymeric 
solutions were combined and allowed to stir for 1 hour until a homogenous state was 
achieved. The lyophilized microparticles were uniformly dispersed within this polymeric 
emulsion and added drop-wise into a 2%w/v calcium hydroxide crosslinking solution. 
The gastrospheres were allowed to cure for 30 minutes, after which they were filtered, 
washed and frozen at -72°C for 24 hours. The frozen gastrospheres were 
subsequently lyophilized at -60°C for a further 24 hours. 
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4.2.2.4. Yield and drug entrapment of microparticles 
The dry weight of the formed microparticles and gastrospheres was measured and 
compared to the weight of the initial dry formulation components. Drug entrapment 
efficiency of the microparticles was determined by dissolving 50mg microparticles in 
100mL simulated gastric fluid (SGF) (pH 1.2, 37°C). Ciprofloxacin content was 
measured in triplicate using UV-spectroscopy at 280nm. The entrapment efficiency 
(DEE) was calculated using equation 3.1 (Streubel et al., 2002). 
 
4.2.2.5. In vitro drug release studies 
Drug release studies were conducted on microparticles as well as microparticle loaded 
gastrospheres employing the USP 32 apparatus 2 dissolution test (Erweka DT 700, 
Heusenstamm, Germany). A modification to the approach was made by immersing the 
samples under a ring mesh assembly (Pillay and Fassihi, 1999) in 900mL simulated 
gastric fluid (SGF) (pH 1.2, 37°C) at a rotation speed of 50rpm. Microparticles were 
weighed and placed in a tea bag which was closed with thread. The tea bag was 
subsequently placed below the ring mesh assembly. Samples of 5mL were removed at 
predetermined time intervals and filtered through a 0.45µm Millipore Millex filter. Equal 
volumes of fresh SGF were replaced in order to maintain sink conditions.  Samples 
were then analysed with UV spectroscopy (CE 3021, Cecil Instruments, Cambridge, 
England) at 280nm. All experiments were conducted in triplicate. The release data was 
subjected to a model-independent analysis known as the time-point approach. Briefly, 
the Mean Dissolution Time set at 12 hours (MDT12) for each formulation was 
calculated. The application of the MDT12 approach provided a more precise analysis of 
the ciprofloxacin release performance for comparison of several release data sets. 
Equation 3.2 was employed in this regard (Hopfenberg and Hsu, 1978; Pillay et al., 
1999). 
 
4.2.2.6. Constraint optimization of formulation responses 
A model-independent approach (Minitab® V15, Minitab Inc., PA USA) was used to 
optimize the microparticle loaded gastrospheres. The independent formulation 
variables were the concentrations of chitosan and Eudragit® employed in the 
formulation of the microparticles. Statistical optimization was therefore employed to 
ascertain the ideal polymeric combination with the desired physicochemical properties 
capable of attaining a maximum drug entrapment efficiency, microparticle yield and 
MDT12 value of 34.833 which conforms to zero-order kinetics over 12 hours. 
 
 
67 
 
4.2.2.7. Fourier Transform Infrared characterisation 
FTIR spectroscopy was performed on the microparticles and the polymers in their 
native form as well as the microparticles and gastrospheres individually and in 
combination. Samples were analysed with a Spectrum 2000 FTIR spectrometer with a 
MIRTGS detector (PerkinElmer Spectrum 100, Beaconsfield, UK). The spectrum was 
a ratio spectrum of 16 sample scans against 16 background scans with a resolution of 
4cm-1. Samples were analysed at wave numbers ranging from 4000-400 cm-1. 
 
4.2.2.8. Characterisation of surface morphology 
SEM analysis was carried out using a Phenom™ scanning electron microscope (FEI 
Company, OR, USA). Samples were made electrically conductive prior to analysis 
through the process of gold-sputter coating (SPI Module™ Sputter Coater, SPI 
Supplies, PA, USA). 
Samples were attached to an SEM stub using adhesive carbon tape. The stub was 
inserted into the stub holder thereafter putting the glass chamber and sputter head in 
place. Argon gas was allowed to flush the system before the leak valve was sealed 
and the vacuum was turned on. The sputter coater was turned on for 90 seconds when 
plasma current reached 18mA, after which the system was turned off and the vacuum 
released. 
 
4.2.2.9. Atomistic molecular structural mechanics simulations 
Molecular Mechanics Computations in vacuum, which included the model building of 
the energy-minimized structures of polymer-polymer and polymer-crosslinker 
complexes, were performed using the HyperChemTM 8.0.8 Molecular Modelling 
System (Hypercube Inc., Gainesville, Florida, USA) and ChemBio3D Ultra 11.0 
(CambridgeSoft Corporation, Cambridge, UK) (Kumar et al., 2011). The structures of 
Eudragit® (E100-five monomer units) and TPP were generated as a 3D model from 
standard bond lengths and angles employing ChemBio3D Ultra whereas the structure 
of chitosan (CHT-ten glucosamine oligosaccharide units) was generated using sugar 
builder module on HyperChem 8.0.8. The generation of the overall steric energy 
associated with the energy-minimized structures was initially executed initially via 
energy-minimization using MM+ force field and the resulting structures were again 
energy-minimized using the Amber 3 (Assisted Model Building and Energy 
Refinements) force field. The conformer having the lowest energy was used to create 
the polymer-crosslinker complexes. A complex of one molecule with another was 
assembled by disposing them in a parallel way, and the same procedure of energy-
minimization was repeated to generate the final models: CHT-EUD and CHT-TPP. Full 
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geometry optimizations were carried out in vacuum employing the Polak–Ribiere 
conjugate gradient method until an RMS gradzient of 0.001kcal/mol was reached. 
Force field options in the AMBER (with all hydrogen atoms explicitly included) and 
MM+ (extended to incorporate non-bonded cut-offs and restraints) methods were the 
HyperChem 8.0.8 defaults. For calculations of energy attributes, the force fields were 
utilized with a distance-dependent dielectric constant scaled by a factor of 1. The 1-4 
scale factors are following: electrostatic 0.5 and van der Waals 0.5. 
 
4.3. RESULTS AND DISCUSSION 
4.3.1. Preparation of microparticles 
Table 4.2 shows the Face-Centered Central Composite Design template generated 
and lists the independent formulation variables considered. 
 
Table 4.2: Face-Centered Central Composite Design template with statistically 
generated formulations 
 StdOrder RunOrder PtType Blocks [CHT] [EUD] 
1 4 1 1 1 1.5 2.00 
2 3 2 1 1 0.5 2.00 
3 7 3 0 1 1.0 1.25 
4 5 4 0 1 1.0 1.25 
5 1 5 1 1 0.5 0.50 
6 2 6 1 1 1.5 0.50 
7 6 7 0 1 1.0 1.25 
8 11 8 -1 2 1.0 2.00 
9 9 9 -1 2 1.5 1.25 
10 12 10 0 2 1.0 1.25 
11 14 11 0 2 1.0 1.25 
12 12 12 0 2 1.0 1.25 
13 8 13 -1 2 0.5 1.25 
14 10 14 -1 2 1.0 0.50 
 
4.3.2. Determination of the yield and drug entrapment efficiency 
Yield of the microparticles was relatively high, ranging from 77 to 92%, with one out 
lying result at 65%, whereas drug entrapment efficiency was within a range of 50% to 
73% (Figure 4.1). The polymer which appears to have the largest impact on DEE is 
Eudragit®. DEE is in the lower range in the formulations where Eudragit® is either at its 
highest (2%w/v) or lowest (0.5%w/v) concentrations, whereas DEE is at its maximum 
when Eudragit® is midway at 1.25%w/v. Chitosan appears to be responsible for 
microparticle yield where yield is highest when chitosan concentrations are highest 
(1.5%w/v) and yield is lowest with chitosan in low concentrations (0.5%w/v). 
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Figure 4.1: Graph illustrating results of DEE and microparticle yield (N=3, SD<7.4). 
 
4.3.3. In vitro drug release analysis 
Drug release profiles obtained from the microparticle formulation 5 is depicted in 
Figure 4.2a. It was observed that drug release followed a first-order release profile, 
although almost 90% of drug was released within the first 4 hours.  
Drug release from the microparticle loaded gastrospheres resulted in an initial burst 
release followed by zero order release as shown in Figure 4.2b for the drug release 
profile of formulation 5. It is evident that the incorporation of the microparticles within 
the gastrospheres resulted in drug release of a more controlled manner and over an 
extended period of time. Table 4.3 gives the MDT12 values obtained from all 14 
formulations which were employed as a factor for constraint optimization. Eudragit® 
appears to impact in vitro drug release more significantly than chitosan. MDT12 is 
greatest when Eudragit® is at a moderate concentration of 1.25%w/v, and decreases 
when Eudragit® concentrations are at their highest (2%w/v) or lowest (0.5%w/v). In most 
cases, MDT12 increased as chitosan concentrations increased. 
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a)
b)
 
Figure 4.2: Drug release of ciprofloxacin in SGF (pH 1.2) from a) microparticles for 
formulation 5 (N=3, SD<0.14 ); and b) microparticle loaded gastrospheres for 
formulation 5 (N=3, SD<0.032) over 12 hours.  
 
Table 4.3: MDT12 values obtained from in vitro drug release studies of ciprofloxacin 
from microparticle loaded gastrospheres (N=3, SD<0.74) 
F# MDT12 
1 29.78 
2 29.79 
3 32.24 
4 32.07 
5 30.82 
6 29.48 
7 32.4 
8 29.33 
9 34.91 
10 31.87 
11 32.10 
12 32.00 
13 32.47 
14 25.36 
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4.3.4. Analysis of the Central Composite Design 
MDT12, DEE and yield for the synthesized formulations were included in the statistical 
design for the identification of the optimal formulation. Residual plots for MDT12, DEE 
and yield are illustrated in Figure 4.3. There was generally a good scattering of points, 
although slight clustering was observed for MDT12 (Figure 4.3(a)). The normal 
probability plots of the residuals for DEE and yield (Figure 4.3(b and c)) show a 
uniform distribution along the straight line, indicating that the data was normally 
distributed without outside influences. The histogram of the residuals for yield (Figure 
4.3(c)) is slightly shifted to the right, showing that the frequency of residuals was not 
evenly distributed. 
 
72 
 
a)
b)
c)
 
Figure 4.3: Residual Plots generated for a) MDT12 b) DEE and c) microparticle yield. 
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The complete regression equations generated for MDT12, DEE and yield are indicated 
below:  
 
MDT12 = 27.6459 - 16.5178[CHT] + 19.2890[EUD] + 7.88542[CHT*CHT] – 
7.78354[EUD*EUD] + 0.890252[CHT*EUD] 
         [Equation 4.1] 
 
DEE = 63.1551 - 2.137[CHT] + 17.2748[EUD] - 2.35733[CHT*CHT] - 
10.1321[EUD*EUD] + 2.87333[CHT* EUD]      
         [Equation 4.2] 
 
Yield = 54.5488 + 45.8487[CHT] + 1.12296[EUD] - 9.50267[CHT*CHT] + 
3.48326[EUD*EUD] - 12.3467[CHT* EUD]   
[Equation 4.3] 
 
4.3.5. Surface response analysis 
4.3.5.1. Mean Dissolution Time  
The effect of factor CHT and EUD on response MDT12 is shown in Figure 4.4(a). Over 
the entire range of factor CHT, an increase in factor EUD from 0.5 to 1.5% w/v resulted 
in an increase of MDT12, although a further increase to 2% w/v resulted in the reduction 
of MDT12. Over the entire range of factor EUD, an initial increase in factor CHT from 
0.5 to 1% w/v resulted in a reduction of MDT12, although an increase in MDT12 was 
observed when factor CHT was increased from 1 to 1.5% w/v. Optimal MDT12 is seen 
when Eudragit® RL 100 30D, which possesses high swelling and permeability, is used 
in moderate concentrations.  The influence of Eudragit® on drug release can be 
explained as follows: A low concentration of Eudragit® may lead to the formation of a 
less dense polymer complex resulting in the loosening of chains, making the hydrogel 
matrix more porous. In the case of high polymer content, there is a greater hydrophilic 
polymer content in the matrix, which may in turn lead to polymer dissolution and water 
penetration causing a rapid drug release. For a given amount of Eudragit® and TPP, 
an increase in chitosan concentration may cause an increase in MDT due to enhanced 
complexation with Eudragit® and the formation of more intermolecular crosslinks with 
TPP as explained further in molecular mechanics simulations. 
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4.3.5.2. Drug Entrapment Efficiency 
The effect of factor CHT and EUD on response DEE is shown in Figure 4.4(b). At low 
levels of factor CHT, DEE is high. An increase in factor EUD from 0.5 to 1%w/v results 
in the increase in DEE, although a further increase to 2% w/v resulted in the reduction 
of DEE. At high levels of factor CHT, DEE was low. The same effect was observed 
with the gradual increase in factor EUD. At low levels of factor EUD, DEE was high, 
decreasing as the level of factor CHT increases. At high levels of factor EUD, DEE 
was low. Minimal change in DEE was observed as the level of CHT is increased. A low 
concentration of Eudragit® may form a loose network resulting in leaching out of drug 
from the polymer matrix during microparticle formation. Additionally, higher 
concentrations of Eudragit® may lead to formation of too dense a network making it 
difficult for the drug molecules to get into the polymer matrix. Furthermore, this may be 
due to the premature swelling of the microparticle matrix, resulting in excessive loss of 
drug in the crosslinking solution. 
 
4.3.5.3. Microparticle Yield 
The effect of factor CHT and EUD on response yield is shown in Figure 4.4(c). At low 
levels of factor CHT, yield is low. An increase in factor EUD resulted in an increase in 
yield. At high levels of factor CHT, yield was high, reducing with the increase in factor 
EUD. At low levels of factor EUD, yield was high, reducing as the level of CHT 
decreases.  At high levels of factor EUD, yield was moderate. Not much change in 
yield was observed over the range of factor CHT. The increased yield can be 
associated with the increase in viscosity of the polymer solution with an increase in 
chitosan concentration. As the polymer solution becomes more viscous it becomes 
more resistant to fragmentation into small droplets which, in turn, may leads to the 
generation of larger microparticles having less surface area and more drug 
entrapment. A lesser surface area may utilise the crosslinking more efficiently leading 
to formation of more and denser microparticles ultimately increasing the % yield. 
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Figure 4.4: Response surface plots depicting the effect of polymer concentrations on: 
a) MDT12, b) DEE, and c) microparticle yield. 
 
4.3.6. Response optimization 
Response optimization (MINITAB®, V14, Minitab, USA) was used to obtain the 
optimized levels of chitosan and Eudragit®. One optimal formulation was developed 
following constrained optimization of MDT12, DEE and microparticle yield. An MDT12 
value representing first order drug release over a period of 12 hours was targeted 
(MDT12=34.883). Figure 4.5 shows the desirability plots of each constraint for the 
optimized formulation. The optimized levels of the independent variables that would 
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achieve the desired drug entrapment, yield and dissolution are represented in Table 
4.5. Table 4.6 shows the optimized levels of the independent variables, the predicted 
response, the desirability score as well as the correlation co-efficient for each 
response. Based on the statistical desirability function, it was found that the desirability 
for the formulations was > 0.9. The constrained settings utilized are outlined in Table 
4.4. 
 
Table 4.4: Formulation constraints employed for response optimization 
Responses Limits 
DEE 
Yield 
Maximum 
Maximum  
MDT12 34.883 
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Figure 4.5: Desirability plots depicting the requisite variables for producing 
microparticles with the desired targeted responses. 
 
Table 4.5: Optimized formulations obtained via the surface response method 
Microparticle Formulation Chitosan (%) Eudragit® RL 100 30D (%) 
1 1.5 1.0741 
 
The ideal formulation was prepared according to the optimal predicted settings. The 
experimentally derived values for MDT12, DEE and yield of the optimized formulation 
were in close agreement with the predicted values (Table 4.6), demonstrating the 
reliability of this optimisation procedure.  
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Table 4.6: Experimental and predicted response values for the optimised  
 Desirability Predicted 
response 
Actual 
Response 
MDT12 0.88969 33.7843 32.2048 
DEE 0.68320 66.1404 59.23 
Yield 0.81341 87.2733 86.743 
 
Simultaneous optimisation of MDT12, DEE and yield resulted in the production of an 
optimum microparticle loaded gastrosphere. The dissolution profile (Figure 4.6) of the 
optimum gastric retentive formulation depicts the control of drug release in a near zero 
order manner as was required.  
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Figure 4.6: Drug release profile for ciprofloxacin for optimized formulation (N=3, 
SD<0.031). 
 
4.3.7. FTIR characterisation 
Figure 4.7 shows a comparison of the structural patterns between the microparticle 
and its component polymers. NH stretching vibrations (3300–3500cm-1) present in the 
chitosan and Eudragit® is still present in the formed microparticle. C=O stretching 
vibrations visible in the Eudragit® between 1700 and 1900cm-1 are still present in the 
microparticle formulation, although to a lesser degree. C-H bands (2800–2950cm-1; 
1355-1395cm-1; 1405-1465cm-1; 1430-470cm-1) are present in all spectra. The C=O 
ester (1730cm-1) visible in Eudragit® is no longer present in the microparticle, evidence 
of the breakage of this bond. 
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Figure 4.7: FTIR spectra of the component polymers and microparticles. 
 
It can be seen in Figure 4.8 that the strong bands observed at ±3200cm-1 in both the 
microparticles and gastrosphere is still present when the microparticles are loaded 
within the gastrosphere. The numerous peaks seen between 900 and 1600 cm-1 show 
an accumulative effect when combined. This proves that no interaction occurred 
between the microparticles and gastrospheres thereby implying that drug release 
follows a two phase diffusion model.  
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Figure 4.8: FTIR spectra of the gastrospheres and microparticles individually and in 
combination. 
 
4.3.8. Surface characterisation by SEM analysis 
A scanning electron microscope image of the optimized microparticle formulation is 
shown in Figure 4.9(a).Smooth-edged, spherical microparticles ranging from 1 to 4µm 
in diameter are visible. The shape of these microparticles are ideal as the forces of 
friction between particles is minimized, resulting in good flow properties. Surface 
morphology of the microparticle loaded gastrospheres is shown in Figure 4.9(b). Air 
pockets or voids are visible just below the gastrosphere surface. These pockets are 
due to the sublimation of water crystals during the lyophilisation process and result in 
the buoyancy of the drug delivery system.  
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Figure 4.9: SEM images of a) microparticle (magnification: 2640x); and b) 
microparticle loaded gastrosphere (magnification: 215x). 
 
4.3.9. Molecular mechanics assisted model building and energy refinements 
The performance of the Ca2+ crosslinked Alg-Pec-PAA-PLGA and the interaction of 
Alg-Pec-PAA-PLGA-Ca2+ with glycosylated gastric mucopeptide analogue, has been 
discussed in Chapter 3. 
A molecular mechanics conformational searching procedure was employed to acquire 
the data employed in the statistical mechanics analysis, and to obtain differential 
binding energies of a Polak–Ribiere algorithm and to potentially permit application to 
complexation and crosslinking of chitosan with/by EUD and TPP respectively. MM+ is 
a HyperChem modification and extension of Norman Allinger's Molecular Mechanics 
program MM2 (Warhurst et al., 2003) whereas AMBER, is a package of computer 
programs for applying molecular mechanics, normal mode analysis, molecular 
a) 
b) 
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dynamics and free energy calculations to simulate the structural and energetic 
properties of molecules. 
 
4.3.10. Molecular mechanics energy relationship analysis 
Molecular mechanics energy relationship (MMER), a method for analytico-
methematical representation of potential energy surfaces, was used to provide 
information about the contributions of valence terms, noncovalent Coulombic terms, 
and noncovalent van der Waals interactions for the complexed/crosslinked 
morphologies. The MMER model for the potential/steric energy factors in various 
molecular complexes can be written as: 
 
Emolecule/complex = V∑ = Vb + Vθ + Vφ + Vij + Vhb + Vel                
[Equation 4.4] 
ECHT =35.555V∑ = 3.120Vb + 18.035Vθ + 25.774Vφ + 13.323Vij - 24.697Vel              
[Equation 4.5] 
EEUD = 45.892V∑ = 4.198Vb + 30.278Vθ + 9.398Vφ + 2.017Vij     
[Equation 4.6] 
EEUD-CHT = 94.699V∑ = 11.435Vb + 72.059Vθ + 57.228Vφ - 21.148Vij - 0.597Vhb - 24.277Vel  
[Equation 4.7] 
[ΔEBINDING = -78.532kcal/mol] 
ETPP = 199.744V∑ = 1.927Vb + 93.088Vθ + 1.599Vφ + 0.046Vij + 103.082Vel   
[Equation 4.8] 
ECHT-TPP = 901.408V∑ = 18.542Vb + 514.621Vθ + 54.501Vφ + 28.920Vij - 1.065Vhb + 285.889Vel  
                            [Equation 4.9] 
[ΔEBINDING = -132.867kcal/mol] 
 
where, V∑ is related to total steric energy for an optimized structure, Vb corresponds to bond 
stretching contributions (reference values were assigned to all of a structure's bond lengths), Vθ 
denotes bond angle contributions (reference values were assigned to all of a structure's bond 
angles), Vφ represents torsional contribution arising from deviations from optimum dihedral 
angles, Vij incorporates van der Waals interactions due to non-bonded interatomic distances, 
Vhb symbolizes hydrogen-bond energy function and Vel stands for electrostatic energy. 
 
4.3.11. 3D-computational modelling for polymer-polymer complexes 
The observed sustained drug release behaviour of the microparticluate matter 
consisting of chitosan and Eudragit® forming a polymeric matrix may depend on 
confound geometry and the extent of network innervations. We hereby enquire, using 
molecular mechanics simulations, the requirement of geometrically proportional 
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networks for all simulations to systematically control and isolate the effects of a given 
parameter. Therefore, for carrying out the static lattice atomistic simulations for the 
polymer-polymer complexes in vacuum, we used the three representative networks 
shown in Figure 4.10 for our measurements and randomly disposed EUD around CHT 
to form EUD-CHT polymeric complex. 
 
It is evident from Equations 4.5-4.7, that the formation of EUD-CHT (in vacuum) was 
accompanied by energy stabilization of -78.532kcal/mol. Molecular modelling studies 
can account for specific interactions between polymer segments and may provide an 
estimate of whether two polymers will form a compatible blend and a necessary 
condition for the miscibility of a mixture of two polymers is a negative free energy of 
mixing (Tiller and Gorella, 1994). This confirms the compatibility of CHT and EUD and 
stability of the microparticluate system in dried state. The energy data displayed very 
interesting results as follows: the total electrostatic energy of the complex (Equations 
4.5-4.7) remained approx. the same ruling out the possibility of any electrostatic 
attraction or repulsion. However, energy of H-bonding of the complex was stabilized 
with -0.598kcal/mol as compared to no H-bonding energy in case of both the polymers. 
The possible H-bonding between CHT and EUD is evident from Figure 4.10 where it is 
demonstrated to be forming -C=O…H-O-C, C-O-C…H-O-C and C-O-C…H-N between 
EUD and CHT, respectively. But the main energy stabilization was contributed by van 
der Waals forces in the form of hydrophobic interactions where an initial combined van 
der Waals energy of ~20kcal/mol (CHT + EUD3) was minimized to -21.148kcal/mol 
(CHT-EUD3) leading to ΔEvdw-binding of 40.5201kcal/mol. This confirms the heavy 
involvement of non-bonding interactions in form of H-bonding and van der Waals 
forces. These underlying chemical interactions may cause conformational changes 
responsible for mechanical strength and drug release characteristics of the 
multiparticulate polymer composite. The stabilization of the structure is clearly obvious 
from rotation of the glucosamine residues of chitosan producing strain due to steric 
interactions which in turn are relieved by the inclusion of bond length and angle 
adjustment after interaction with Eudragit® molecules. These steric adjustments were 
appeared to be responsible for the formation of H-bonds between CHT and EUD as 
explained above. The aliphatic/hydrophobic groups of EUD moved along with hydroxyl 
and NH2 groups of HPMC to their nearest minimum from the starting point during 
minimization, driving the molecule through unfavourable regions. Additionally, the 
resulting large steric interactions may cause the non-interacting groups to overcome 
torsional barriers presenting a highly dense polymeric matrix (Figure 4.10c) causing a 
prolonged release of the drug from microparticles. 
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Although the CHT-EUD polymeric complex was stabilized by non-bonding interactions, 
the inherent bonding interaction in the form of high bond energy (11.435kcal/mol), high 
angle energy (72.06kcal/mol) and high dihedral energy (57.228kcal/mol) may induce 
degradation of the polymeric matrix in a quest to attain further energy stabilization on 
hydration. This makes the hydrophilic polymers, such as chitosan, containing 
complexes vulnerable to hydration leading to early release of drug due to diffusion of 
water molecules inside the torsional restraints. Additionally, this may cause loosening 
of the network structure (Figure 4.10c) that may allow for the leaching out of drug 
particles during microparticles preparation eventually affecting the encapsulation 
efficiency (Kumar and Bhatia, 2010). These observations lead to the postulation that 
the chitosan (the hydrophilic polymer) should be crosslinked in order to get a dense 
and rigid network causing retention of more drug particles during microparticles 
preparation and also for prolonged drug release as explained further in this discussion. 
 
4.3.12. 3D-conputaional modelling for crosslinked-polymer complexes 
The chitosan present in the microparticulate polymeric matrix in particular was further 
stabilized and crosslinked due to the addition of sodium tripolyphosphate (TPP) as 
shown in Figure 4.11 and Equations 4.6, 4.8 and 4.9. The CHT-TPP complex was 
mainly stabilized by nonbonding interactions in terms of London dispersion forces, H-H 
bonding and ion pair-ion pair electrostatic interactions where the molecular complex 
demonstrated a ΔEBINDING of -132.867kcal/mol (Equations 4.6, 4.8 and 4.9). The direct 
linking of adjacent glucosamine units could have been responsible for bringing about 
the definitive change in inherent energy attributes relative to uncrosslinked state. The 
crosslinking of CHT by TPP was evident from the formation of PO4-…O-H crosslinks, 
PO4-…N-H crosslinks, O-H…PO4-…O-H crosslinks, N-H…PO4-…N-H crosslinks and 
O-H…PO4-…N-H crosslinking. Furthermore, this may also initiate an intermolecular 
crosslinking leading to a significant axial stress due to buildup of the adjacent 
crosslinks (Figure 4.12). This provides a reasonable explanation for the experimentally 
observed controlled release behaviour of the microparticle formulations due to 
formation of a dense polymeric matrix owing to this very crosslinking mechanism of 
TPP and the complexation of CHT and EUD.  
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a)
b)
c)
 
Figure 4.10: a and b) Visualization of geometrical preferences of EUD (stick rendering 
- yellow) in complexation with CHT (tube rendering - red) after molecular mechanics 
simulations; c) The dense polymeric matrix is encircled in the Connolly molecular 
electrostatic potential surfaces in translucent display mode. Colour codes: C (cyan), O 
(red), N (blue) and H (white). 
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a)
b)
 
Figure 4.11: a) Visualization of geometrical preferences of TPP (stick rendering) in 
complexation with CHT (tube rendering) after molecular mechanics simulations; and b) 
The Connolly molecular electrostatic potential surface of crosslinked polymeric matrix 
in translucent display mode.   Colour codes: C (cyan), O (red), N (blue), P (yellow) and 
H (white). 
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a)
b)
 
Figure 4.12: a) Visualization of geometrical preferences of intermolecular crosslinking 
of CHT (tube rendering) by TPP (stick rendering) after molecular mechanics 
simulations; b) The Connolly molecular electrostatic potential surface of 
intermolecularly crosslinked polymeric matrix in translucent display mode. Colour 
codes: C (cyan), O (red), N (blue), P (yellow) and H (white). 
 
4.4. CONCLUDING REMARKS 
In this chapter, the Central Composite Design was applied for the development and 
optimisation of a novel microparticle entrapped gastrosphere to deliver ciprofloxacin in 
a gastric retentive manner. The design generated 14 microparticulate formulations, 
which varied in their drug entrapment, yield and release characteristics. Regression 
analysis demonstrated the agreement between the predicted and observed responses 
obtained, indicating the applicability of the models generated by the Central Composite 
Design. Optimisation of the design resulted in the production of an optimal formulation 
having a DEE of 59.23%, yield of 86.743% and a MDT12 of 32.2058, which was 
capable of obtaining a near zero-order drug release over a period of 12 hours. Overall, 
the experimental findings were well corroborated by the chemometric modelling. 
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CHAPTER 5 
In Vivo Analysis of Drug Delivery Systems 
 
5.1. ANIMAL STUDIES 
5.1.1. The swine animal model 
There are several factors to take into account when selecting an appropriate animal 
model for biomedical research, these include: the cost of the animal, ease of handling 
and housing, breeding time, longevity and whether it meets size requirements (Mullen 
et al., 1992; Pennington, 1992; Sachs, 1992; White et al., 1992). There is no animal 
which perfectly satisfies all the requirements of an ideal animal model as a 
replacement for human studies (Pennington, 1992; White et al., 1992). Although dogs, 
cats and primates have been used in the past in biomedical research, there is a 
growing resistance to this due to high cost and pressure from special interest groups 
(Mullen et al., 1992). The use of pigs in this field has increased steadily over the past 
decade due to the great similarities between human and swine anatomy and 
physiology, as well as meeting many of the above mentioned factors (Sachs, 1992). It 
is however, important that all personnel are knowledgeable in the proper care and 
handling techniques of swine, as well as the irregularity of anaesthesia induction (Bloor 
et al., 1992). The majority of porcine biomedical research is conducted on immature 
domestic pigs, with researchers extrapolating the results to the human adult (Hannon, 
1992). With particular importance to this study, basal and histamine-stimulated release 
of pepsin and gastric acid is exhibited by pigs (Hannon, 1992). 
 
5.1.2. Methods 
5.1.2.1. Implantation of chronic catheter 
A pig weighing 35-45kg was anaesthetised with ketamine (11mg/kg I.M.) and 
midazolam, (0.3mg/kg I.M.). Buprenorphine (0.05mg/kg I.M.) and carpofen (4mg/kg 
I.M.) were administered for analgesia and inflammation. The pig was then intubated 
and anaesthesia was maintained with 2% isoflurane in 100% oxygen. Under aseptic 
conditions, a 7 french gauge double lumen 35cm catheter (CS-28702) (Arrow 
Deutschland GmdH, Erding, Germany) was surgically inserted into the left jugular vein 
as depicted in Figure 5.1. The jugular vein was exposed by an incision made dorsal to 
the jugular groove on the left lateral aspect of the neck. Via blunt dissection, the vein 
was isolated and the catheter was inserted 10cm into the lumen of the vein. The lumen 
of the catheter was fastened to the wall of the vein using a purse suture technique. 
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The remaining length of the catheter (25cm) was tunnelled subcutaneously, with the 
use of trocar, to an exit point cranial to the dorsal aspect of the scapular. Both the 
incision and exit points were sutured. The externalised injection ports of the catheter 
were sutured to the skin of the pig so as to limit excessive movement and bending. 
Blood was removed via the catheter and the catheter was flushed with heparin saline 
(1000 i.u. of heparin in 1L of 0.9% saline). Thereafter the animal was allowed 8 days to 
recover from the surgical procedure. During this time, it was habituated to the process 
of blood sampling. Throughout the study, the catheter was flushed with heparinised 
saline three times a day. 
 
a) b) c)
d) e)  
Figure 5.1: Digital images depicting the surgical procedure for the implantation of the 
chronic catheter a) isolation of jugular vein, b) insertion of the catheter through the wall 
of the vein, c) subcutaneous tunneling of catheter through a trocar, d) sutures of the 
incision and e) suturing of catheter ports and exit point. 
 
5.1.2.2. Administration of drug delivery system 
Dormicum® and Anaket® was injected directly into the jugular vein catheter. Once 
sedated, the pig was anaesthetised with 2% isoflurane in 100% oxygen. An intragastric 
tube was inserted into the stomach of the pig, and the delivery system was washed 
down the tube with 50mL water as depicted in Figure 5.2. While under sedation, all 
wounds were checked and sutures were repaired. The pig was returned to its pen to 
recover under observation. A summary of the in vivo study is illustrated in Figure 5.3. 
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a) b)  
Figure 5.2: Digital images depicting the administration of the drug delivery system a) 
anesthetisation of the sedated pig using isoflurane gas and b) administration of 
capsules through an intragastric tube. 
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Figure 5.3: Summary of the in vivo study. 
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5.1.2.3. Sampling of blood 
Blood samples were taken over a 24 hour period. Two hour intervals were utilised for 
the first 12 hours, thereafter, samples were taken every four hours for the remaining 12 
hours. 
The catheter was disinfected and an aseptic technique was utilised to prevent the 
introduction of foreign organisms. Before blood was sampled, the catheter was flushed 
with heparinised saline in order to clear any clots and remove old blood. Thereafter, 
blood was drawn and placed in a lithium heparin Vacutainer®. The catheters were once 
again flushed with heparinised saline. Blood samples were centrifuged at 5000rpm for 
15 minutes. The plasma was removed and frozen at -72°C until required. 
 
5.2. ANALYSIS OF BLOOD SAMPLES 
5.2.1. Liquid Chromatography 
Liquid chromatography is a technique which is widely used in order to control and 
evaluate the quality and consistency of active pharmaceutical compounds in drug 
delivery systems (Dongre et al., 2008). 
Chromatography involves the separation of compounds based on their polarity. This is 
achieved through the principle of ‘like attracts like’. Two phases are required, namely 
the mobile phase and the stationary phase, one of which must be polar, while the other 
is non-polar. Migration of compounds occurs when that compound is in the mobile 
phase. Therefore, compounds which are ‘most like’ the mobile phase in polarity will be 
eluted first, whereas compounds which are ‘least like’ the mobile phase will be eluted 
last. 
 
Selection of the correct mobile and stationary phases is of the utmost importance in 
order to achieve a successful separation. Most commonly, the polarity of the stationary 
phase is matched to that of the compound, and the mobile phase is of opposite 
polarity. This is done in order to ensure that the compound and mobile phase are not 
too similar in polarity, which would result in very little retention, causing the compound 
to become eluted with the void volume of the mobile phase. When the stationary 
phase is more polar than the mobile phase, it is said to be ‘normal phase 
chromatography’, whereas if the mobile phase is more polar than the stationary phase, 
it is termed ‘reverse phase’ (Hamilton and Sewell, 1982; Lim, 1986). Reverse phase 
chromatography is the most commonly used mode of liquid chromatography due to its 
versatility (Lim, 1986). 
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In reverse phase chromatography, the stationary phase consists of silica which is 
chemically bonded with an alkylsilyl compound in order to obtain a non-polar, 
hydrophobic surface (Lim, 1986) and named according to the number of carbon 
groups which have been attached. The most common packaging is the C18 type, 
although they are available from C1 up to C22 (Lim, 1986). The retention of compounds 
is usually proportionate with the length of the bonded carbon group. 
 
The mobile phase may be a single solvent, or a combination of numerous solvents 
(Hamilton and Sewell, 1982). Besides the polarity, other characteristics such as 
viscosity, volatility, refractive index and UV absorption may influence the scientist’s 
decision in the selection of an appropriate mobile phase (Hamilton and Sewell, 1982). 
Separations may be run isocratically (the composition of the mobile phase is kept 
constant) or in a gradient method (the mobile phase composition changes during the 
elution, including changes in pH or ionic strength) (Pryde and Gilbert, 1979). 
 
Internal standards, which are added to the solution before it is analysed, are commonly 
used in liquid chromatography in order to eliminate apparatus and procedural errors 
(Brown, 1973). There are certain requirements which make an internal standard 
suitable for use (Brown, 1973). These are: 
 It must elute near the compound being tested 
 It must be completely resolved from the compound of interest 
 It should be at a similar concentration to the compound of interest 
 It must be chemically inert 
 
5.2.2. Ultra Performance Liquid Chromatography (UPLC) 
UPLC is a relatively new separation technique based on liquid chromatography 
(Dongre et al., 2008). UPLC instruments can run at higher operating pressures (up to 
1000 bars as opposed to a maximum of 400 bars associated with HPLC), and the 
columns are packed with sub-2µm particles. These changes allow for much greater 
resolution in a significantly reduced separation time with high peak capacities (Dongre 
et al., 2008; Wren and Tchlitcheff, 2006). It is because of these improvements in speed 
and sensitivity that UPLC has received much attention from the pharmaceutical 
industry in recent years (Dongre et al., 2008; Wren and Tchlitcheff, 2006) 
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5.2.3. UPLC analysis of metformin loaded gastrospheres 
5.2.3.1. Materials and Methods 
5.2.3.1.1. Reagents 
Metformin (MET) and the internal standard, diphenhydramine (DPH) were purchased 
from Aldrich Chemistry (Sigma-Aldrich, Steinheim, Germany). Acetonitrile (ACN) and 
methanol (MeOH) were purchased from Romil Ltd (Cambridge, UK), formic acid, 
ammonium solution 25%, NaOH and KH2PO4 were purchased from Rochelle 
Chemicals (Johannesburg, South Africa). Water was deionised and filtered on Millipore 
water purification system (Milli-Q gradient, Mass,USA). 
 
5.2.3.1.2. Preparation of calibration standard solutions and determination of the 
limit of quantification 
Stock solutions of MET (500µg/mL) and internal standard (DPH) (200µg/mL) were 
prepared in deionized water. The MET solution was diluted with deionized water in 
order to prepare spiking solutions of metformin concentrations ranging from 1 to 
500µg/mL. In order to prepare the calibration standards, 50µL aliquots of the spiking 
solutions were added to 150µL blank plasma. The concentrations of plasma calibration 
standards ranged between 25ng/mL and 125µg/mL. Each standard was subjected to 
the solid phase extraction (SPE) procedure as described in 5.2.3.1.4 and was spiked 
with the internal standard (50µL). The samples were then placed in Waters certified 
UPLC injection vials for analysis. A 5µL sample was injected into the UPLC column for 
analysis of metformin content.  
The peak area ratio of MET and the internal standard (DPH) were plotted against the 
concentration for the calibration standards. The means of the least square method, the 
linearity equation and correlation coefficient, was obtained.  
The limit of quantification (LOQ) is determined by calculating the concentration of 
metformin at which the chromatographic peak was equal to 10 and 3 times of the 
baseline noise. 
 
5.2.3.1.3. Sample preparation 
Blood samples were removed from the freezer (-70°C) and thawed. A 150µL aliquot of 
each blood sample was transferred to a centrifuge tube. ACN (150µL) and deionised 
water (50µL) was added to each vial and vortexed. Each tube was subsequently 
centrifuged at 3200rpm for 15 minutes (Optima® LE-80K, Beckman, USA). The 
supernatant was removed and subjected to the SPE procedure described in 5.2.3.1.4 
and spiked with internal standard (DPH) (50µL). The samples were then placed in 
Waters certified vials for analysis.  
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5.2.3.1.4. Extraction of Metformin from porcine plasma samples 
Waters Oasis® WCX 1cc cartridges (Millipore Corporation, Mass, USA) were used in 
order to separate metformin from porcine plasma under vacuum. Figure 5.4 shows the 
procedure that was followed in order to achieve extraction. 
 
 
Figure 5.4: Procedure followed in order to extract metformin from porcine blood 
plasma. 
 
5.2.3.1.5. Chromatographic system and conditions 
All analyses were performed on a Waters Acquity® UPLC system (Waters Corp., 
Milford, MA, USA) including binary solvent manager, sample manager and PDA 
detector, connected to a Waters Empower 2 data station. UPLC separation was 
achieved on an Acquity® UPLC HSS T3 column (2.1mmx150mm I.D. 1.8µm), column 
temperature was set at 30°C. The mobile phase consisted of water and ACN under 
isocratic conditions (ACN-H2O 65:35 v/v) at a flow rate of 0.40mL/min. The total run 
time was 3 min with an injection volume of 5µL. The system was allowed to equilibrate 
for 5 minutes between injections. The photodiode array (PDA) detector was set at 
241nm. 
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5.2.3.2. Results and discussion 
5.2.3.2.1. Chromatograms for standard solutions 
A typical chromatogram of standard solution of MET (Figure 5.5), DPH (Figure 5.6) 
and a plasma sample post-administration of the gastrospheres is displayed in Figure 
5.7. These chromatograms prove that the methods employed for the elution of both 
MET and DPH were successful. 
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Figure 5.5: A typical chromatogram depicting the peak (Rt=0.734) for MET employing 
UPLC at 241nm in water. 
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Figure 5.6: A typical chromatogram depicting the peak (Rt=0.838) for DPH (internal 
standard) employing UPLC at 241nm in water. 
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Figure 5.7: A typical UPLC chromatogram depicting the distinct separation of MET 
(Rt=0.725) and DPH (Rt=0.968) at 241nm from the porcine plasma samples. 
 
5.2.3.2.2. Calibration curve 
Figure 5.8 displays the standard linear curve constructed for the determination 
of MET concentrations in porcine plasma. Good linearity was achieved 
(R2=0.9985). 
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Figure 5.8: Calibration curve of metformin concentrations in blank porcine plasma. 
 
The lower limit of quantification for this study was determined to be 0.742ng/mL. 
 
5.2.3.2.3. In vivo metformin release profile from gastrospheres 
A comparison is made in Figure 5.9 between the metformin plasma concentrations 
obtained after the administration of a single dose of Glucophage® 500, Glucophage® 
XR 500 and the gastrospheres designed in Chapter 3. It can be noted that the 
gastrospheres not only obtain a higher peak plasma concentration, but also results in 
an improvement in the maintenance plasma concentration. 
The original Glucophage® 500 displays the lowest plasma concentrations over the 
entire 24 hours. This results in the requirement for repeated doses every 8 hours.  
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Figure 5.9: In vivo profile for metformin release from Glucophage® 500mg (N=5, 
SD<0.03514 in all cases), Glucophage® XR 500 (N=5, SD<0.03584 in all cases) and 
the gastrosphere drug delivery system (N=5, SD=0.04113 in all cases). 
 
5.2.4. UPLC analysis of ciprofloxacin loaded microparticles 
5.2.4.1. Materials and Methods 
5.2.4.1.1. Reagents 
Ciprofloxacin (CIPRO) was sourced from Fluka Analytical (Sigma-Aldrich, Steinheim, 
Germany) and the internal standard, ranitidine hydrochloride (RAN) was purchased 
from Sigma RBI (Steinheim, Germany). Acetonitrile (ACN) and methanol (MeOH) were 
purchased from Romil Ltd (Cambridge, UK), formic acid, ammonia solution 25% and 
potassium dihydrogen orthophosphate was purchased from Rochelle Chemicals 
(Johannesburg, South Africa). Water was deionised and filtered on Millipore water 
purification system (Milli-Q gradient, Mass,USA). 
 
5.2.4.1.2. Preparation of calibration standard solutions and determination of the 
limit of quantification 
Stock solutions of CIPRO (1µg/mL) and internal standard (RAN) (40µg/mL) were 
prepared. The CIPRO solution was diluted with deionised water in order to prepare 
spiking solutions of CIPRO concentrations ranging between 1.125 and 9µg/mL. In 
order to prepare the calibration standards, 800µL aliquots of the spiking solutions were 
added to 1mL blank plasma. The concentrations of plasma calibration standards 
ranged between 0.5 and 4µg/mL. Each standard was subjected to the SPE procedure 
described in 5.2.4.1.4 and was spiked with the internal standard (20µL). The samples 
were then placed in Waters certified UPLC injection vials for analysis. A 5µL sample 
was injected into the UPLC column for analysis of ciprofloxacin content.  
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The peak area ratio of CIPRO and the internal standard RAN were plotted against the 
concentration for the calibration standards. The means of the least square method, the 
linearity equation and correlation coefficient was obtained.  
The limit of quantification (LOQ) is determined by calculating the concentration of 
ciprofloxacin at which the chromatographic peak was equal to 10 and 3 times of the 
baseline noise. 
 
5.2.4.1.3. Sample Preparation 
Blood samples were removed from the freezer (-70°C) and thawed. A 1mL aliquot of 
each blood sample was transferred to a centrifuge tube. ACN (0.2mL) and deionised 
water (0.8mL) were added to each tube and vortexed and subsequently centrifuged at 
3200rpm for 15 minutes (Optima® LE-80K, Beckman, USA). The supernatant was 
removed and subjected to the SPE procedure described in 5.2.4.1.4 and spiked with 
internal standard (RAN) (20µL). The samples were then placed in Waters certified vials 
for analysis.  
 
5.2.4.1.4. Extraction of ciprofloxacin from plasma samples 
Waters Oasis HLB 3cc cartridges (Millipore Corporation, Mass, USA) were used in 
order to separate ciprofloxacin from plasma under vacuum. Figure 5.10 shows the 
method which was carried out in order to achieve this.  
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Figure 5.10: Procedure followed to extract ciprofloxacin from porcine blood plasma. 
 
5.2.4.1.5. Chromatographic system and conditions  
All analyses were performed on a Waters Acquity® UPLC system (Waters Corp., 
Milford, MA, USA) including binary solvent manager, sample manager and PDA 
detector, connected to a Waters Empower 2 data station. UPLC separation was 
achieved on an Acquity® UPLC BEH shield Reverse Phase C18 column 
(2.1mmx100mm I.D. 1.7µm), column temperature was set at 25°C. The mobile phase 
consisted of buffer and ACN under gradient conditions as shown in Table 5.1 at a flow 
rate of 0.40mL/min. The total run time was 5 min with an injection volume of 5µL. The 
photodiode array (PDA) detector was set at 280nm. 
  
Table 5.1: Gradient UPLC methodology for the detection of CIPRO and the IS (RAN). 
Time (min) Flow (mL/min) % Buffer % ACN 
0 0.4 90 10 
0.5 0.4 80 20 
3 0.4 90 10 
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5.2.4.1.6. Preparation of mobile phase 
A buffer concentrate was prepared by pouring 200mL deionised water into a 1L 
volumetric flask and adding ammonium solution 25% (3mL) and formic acid (10mL). 
The solution was made up to 1L and shaken. The mobile phase is prepared by taking 
100mL buffer concentrate and making it up to 1L with ionised water. 
 
5.2.4.2. Results and discussion 
5.2.4.2.1. Chromatograms for standard solutions 
A typical chromatogram of standard solution of CIPRO (Figure 5.11), RAN (Figure 
5.12) and a plasma sample post-administration of the microparticle loaded 
gastrospheres is displayed in Figure 5.13. These chromatograms prove that the 
methods employed for the elution of both CIPRO and RAN was successful. 
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Figure 5.11: A typical chromatogram depicting the peak (Rt=1.366) for CIPRO 
employing UPLC at 280nm in water. 
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Figure 5.12: A typical chromatogram depicting the peak (Rt=0.846) for RAN (internal 
standard) employing UPLC at 280nm in water. 
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Figure 5.13: A typical UPLC chromatogram depicting the distinct separation of CIPRO 
(Rt=1.347) and RAN (Rt=0.722) at 280nm from the porcine plasma samples. 
 
5.2.4.2.2. Calibration curve 
Figure 5.14 displays the standard linear curve constructed for the determination of 
CIPRO concentrations in porcine plasma. Good linearity was achieved (R2=0.9984).  
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Figure 5.14: Calibration curve of ciprofloxacin concentrations in blank porcine plasma. 
 
The lower limit of quantification for this study was determined to be 0.317ng/mL. 
 
5.2.4.2.3. In vivo ciprofloxacin release profile from microparticle loaded 
gastrospheres 
The extraction procedure followed in order to remove ciprofloxacin from the porcine 
plasma is obtained from Vybiralova et al. (2005). The chromatographic conditions were 
adapted from Pearce et al. (2009) for the quantitative determination of ciprofloxacin. 
The adaptation has resulted in the easier preparation of mobile phases and thus a 
change in the mobile phases utilised. This method is simple, quick and effective, 
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showing good separation of peaks and complete elution is achieved in less than 2 
minutes under the chromatographic conditions described. 
Drug plasma concentrations can be seen in Figure 5.15. A single dose of Ciprobay® 
250mg and a single dose of microparticle loaded gastrospheres are both represented 
by a curve. It can be seen that the drug concentration is sustained in a controlled 
manner after administration of the microparticle loaded gastrospheres whereas 
ciprofloxacin concentrations steadily decrease after peak concentration is reached 
following administration of Ciprobay®. 
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Figure 5.15: In vivo profile for ciprofloxacin release from Ciprobay® 250 (N=5, 
SD<0.1741 in all cases) and microparticle loaded gastrospheres (N=5, SD<0.1189 in 
all cases). 
 
5.3. CONCLUDING REMARKS 
This study sought to address the in vivo release of metformin and ciprofloxacin with 
the use of SPE and UPLC techniques. 
UPLC analysis was undertaken in order to determine plasma concentrations of 
metformin and ciprofloxacin after the administration of the drug delivery systems 
designed and optimized in chapters 3 and 4 respectively. 
Drug release profiles illustrated superior plasma concentrations of both metformin and 
ciprofloxacin in comparison the gold standard products currently on the market, 
thereby reducing the dosing intervals and ultimately improving patient compliance. 
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CHAPTER 6 
Conclusion and Recommendations 
 
6.1. CONCLUSIONS  
Extensive in vitro testing has resulted in the development of two novel gastroretentive drug 
delivery systems. 
The gastrospheres were optimised employing the Box-Behnken experimental design. 15 
formulations were investigated with respect to yield, buoyancy, mucoadhesion and MDT12. A 
Central Face-Centred design was utilised in order to optimise the microparticle formulation. 
This entailed the investigation of nine formulations with respect to drug entrapment, yield and 
MDT12.  
Extensive tests including water uptake and swelling, surface area and porosity analysis, 
FTIR and SEM were undertaken in order to determine the physicomechanical characteristics 
of the developed drug delivery systems. 
 
Both the gastrosphere delivery system and microparticle loaded gastrosphere delivery 
system displayed effective control over drug release in an in vitro environment. Both delivery 
systems were tested in vivo in the pig model in order to prove this controlled drug release. 
 
The development of effective UPLC and SPE techniques allowed for the testing of in vivo 
porcine plasma samples. Results for both drug delivery systems provide evidence that 
confirms the effective control which has been achieved over the rate of drug release. 
 
6.2. RECOMMENDATIONS 
With these two novel drug delivery systems, I have been able to improve the bioavailability of 
two drugs with opposing aqueous solubilities. A drug delivery platform has therefore been 
developed which would ultimately have the ability to deliver any drug possessing a narrow 
absorption window and low bioavailability. Resulting in single daily dose regimens with fewer 
side effects, improved patient compliance and a greater overall rate of therapeutic success. 
 
These same two platforms may also be adapted for the treatment of specific disease states. 
Peptic ulcers, especially with the presence of H. pylori, may benefit from local treatment. It is 
envisaged that traditional ‘Triple Therapy” which involves the use of a PPI (proton pump 
inhibitor) and two antibacterials namely, amoxicillin and clarithromycin be incorporated into a 
single dose. This would enable both systemic and local eradication of the bacterium. 
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Gastroretentive Drug Delivery Systems: Current Developments in Novel System 
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ABSTRACT: The task of achieving efficient delivery of drugs that have poor bioavailability 
or narrow absorption windows have plagued the pharmaceutically industry for decades. 
Thus, much research has been dedicated to the development of novel polymeric-based 
gastroretentive drug delivery technologies that may optimize the bioavailability and 
subsequent therapeutic efficacy of such drugs. An effective approach of achieving this is 
through the prolongation of the gastric residence time employing several gastroretentive drug 
delivery mechanisms such as the use of buoyant systems, high density systems, magnetic 
systems, mucoadhesive systems, swelling/expanding systems, superporous hydrogels and 
the inclusion of gastric motility retarding agents with biocompatible polymeric materials. It is 
known that variations in the gastric physiology such as, gastric pH, and motility exhibit both 
intra-as well as inter-subject variability demonstrating a significant impact on the gastric 
retention time and drug delivery behavior. Nevertheless, gastroretentive drug delivery 
systems have shown promising results. Therefore, in this mini-review, current research and 
development in this field (i.e. over the last 3-5 years), the polymeric material used for the 
design of gastroretentive drug delivery systems and techniques employed for the 
pharmaceutical evaluation of gastroretentive technologies are comprehensively revealed and 
discussed in an assimilatory manner. 
 
KEY WORDS: Gastric retention, biocompatible polymers, drug delivery, effervescent, 
mucoadhesion, multi-units, expanding, buoyancy, high density, bioavailability  
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Abstract  
In order to overcome poor bioavailability of narrow absorption window drugs, a system 
comprising two mechanisms of gastric retention, namely buoyancy and gastroadhesion has 
been investigated employing poly-lactic-co-glycolic acid (PLGA), polyacrylic acid (PAA), 
alginate and pectin and a model drug metformin hydrochloride. Fifteen formulations were 
obtained using the design of experiments Box-Behnken approach. The yield was found to be 
above 80% in all cases, although due to the high water solubility of metformin, drug 
entrapment efficacy was only between 18 and 54%. Mean dissolution time (MDT) and 
gastroadhesive strength were used as the formulation responses in order to optimize the 
formulation. Furthermore, the molecular mechanics (MM) force field simulations were 
performed to corroborate the experimental findings. Drug release profiles revealed three 
different release kinetics, namely burst; first-order and zero-order release. Varying 
gastroadhesive results were obtained, and were highly sensitive to changes in polymer 
concentrations. FTIR revealed that strong bonds of PAA and PLGA were retained within the 
gastrosphere. Surface area and porosity analysis provided supporting evidence that the 
lyophilization process resulted in a significant increase in the porosity. Analysis of the surface 
morphology by SEM revealed that air pockets were spread over the entire surface of the 
gastrosphere, providing a visual proof of the high porosity and hence low density of the 
gastrosphere. The spatial disposition and energetic profile of the sterically constrained and 
geometrically optimized multi-polymeric complex of alginate, pectin, PAA and PLGA 
corroborated the experimental results in terms of in vitro drug release and gastroadhesive 
strength of the fabricated gastrospheres. 
 
Keywords: Gastrofloatable; Gastroadhesive; Narrow Absorption Window; Buoyant; 
Gastrospheres; PLGA; Box-Behnken 
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Abstract 
In order to develop a drug delivery system which will overcome the shortfalls commonly 
associated with drugs possessing a narrow absorption window, a microparticulate loaded 
gastroretentive drug delivery system has been investigated. This study deals with the 
development of a novel microparticle formulation loaded within a pre-developed 
gastrosphere design which is both gastrofloatable and gastroadhesive. A combination of 
chitosan and polymethacrylate were used in order to form the ioniclly crosslinked 
microparticles, while the gastrospheres were formed from alginate, pectin, poly(acrylic) acid 
and poly(lactic-co-glycolic) acid. A face-centered central composite design was constructed 
for this study which resulted in 14 statistically derived formulations. In order to identify the 
optimal polymeric concentrations, microparticle drug entrapment, microparticle yield and 
mean dissolution time (MDT) were utilized as formulation constraints. Physicochemical and 
morphological characterisation was conducted on the optimized formulation, including 
Fourier Transition Infrared (FTIR) spectroscopy and Scanning Electron Microscopy (SEM) 
characterization. Regression analysis and constraint optimization was utilized in order to 
obtain the optimal formulation. Surface response analysis was utilised in order to determine 
the interactions between chitosan and Eudragit® RL100 30D. To mechanistically elucidate the 
complexation and crosslinking mechanism of Eudragit® and sodium tripolyphosphate with 
respect to chitosan, we employed computer-aided modelling of the three-dimensional 
structure of the active residues of the guest molecules with the respective substrate, to 
predict the possible orientation of residues most likely affecting the drug delivery system’s 
performance. Microparticle yield was relatively high, ranging from 77 to 92%, while drug 
entrapment ranged between 50 to 73%. Drug release profiles displayed an initial burst 
release followed by zero order release over a 12 hour period. FTIR analysis showed no 
chemical interaction occurring between the microparticle and gastrosphere. SEM imaging 
showed that microparticles were uniform and spherical with diameters of between 3 and 
5µm. In vivo drug release was performed a porcine model and displayed more controlled 
release over a 24 hour period when compared to that of Ciprobay®. Overall, the developed 
delivery system may be suitable for the delivery of narrow absorption window drugs. 
 
Keywords: Gastroretentive microparticles, Gastroadhesive drug delivery system, 
Gastrofloatable drug delivery system, Narrow absorption window drugs, Face-centered 
central composite design.  
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Purpose 
Gastroretentive drug delivery systems are intended for the delivery of drugs which 
display a low bioavailability due to a narrow absorption window (eg. metformin). 
Poly(lactic-co-glycolic acid) (PLGA) is an aqueous insoluble polyester which is known 
to control the release of drug over extended periods of time via diffusion, erosion or a 
combination thereof. 
The purpose of this study is to therefore investigate what effect the addition of PLGA 
has on the buoyancy, adhesion and drug release of an alginate/pectin/poly(acrylic 
acid) (PAA) gastrosphere. 
 
Methods 
Preparation of gastrospheres: Three formulations were prepared. All three 
formulations contained 2% w/v pectin, alginate and metformin, in addition to which 
formulation i) contained1% w/v PAA, formulation ii) contained 2% w/v PAA and PLGA 
and formulation iii) contained 2% w/v PAA. 
The polymer solutions were homogenised and added drop-wise with an 18G needle 
into a 2% w/v zinc gluconate solution and left to cure for 24 hours. Each formulation 
was frozen at -72°C for 24 hours and lyophilised at -60°C and 25mmtor for 24 hours. 
Determination of buoyancy: Buoyancy was determined visually, by observing 
gastrosphere characteristics in simulated gastric fluid (pH 1.2; 37°C) agitated in a 
shaker bath (SBS40 Shaking Water Bath, Stuart, New York, USA). 
In Vitro drug release studies: Release studies were conducted in a rotating paddle 
apparatus in simulated gastric fluid (SGF) (pH 1.2; 37°C). 5mL samples were drawn 
at pre-determined intervals over a 12 hour period and analysed by UV 
spectrophotometry. 
Determination of bioadhesion: Bioadhesivity testing was performed using a 
TA.XTplus Texture Analyser (Stable Micro Systems, Surrey, UK) employing a 
simulated GIT membrane surrounding both the textural probe and platform stage. 
Samples were tested using an applied force of 2.00N, a contact time of 15 seconds 
and a trigger force of 0.05N. The pre-test and test speed was set at 0.50mm/sec 
while the post-test speed was maintained at 10mm/sec. 
 
Results 
The studies revealed that the inclusion of PLGA into gastroretentive gastrospheres 
results in a decreased, although more controlled, drug release over the entire 12 
hour period, while only a minimal decrease in bioadhesivity was noted with no 
alteration in buoyancy.  
It can therefore be concluded that the inclusion of PLGA results in a gastrosphere 
which displays an improved and more desirable controlled drug release. 
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Purpose 
In order to extend gastric retention of the drug delivery system, the influence of incorporating 
a bioadhesive polymer, such as poly(acrylic) acid, was assessed. This mechanism it 
intended for the delivery of narrow absorption window drugs that display poor bioavailability. 
Therefore, the purpose of this study is to develop a novel buoyant and gastroadhesive drug 
delivery system for the delivery of narrow absorption window drugs. 
 
Methods 
Preparation of the gastrospheres: Varying concentrations of PAA solutions, ranging 
from 0.5–1.5% w/v, were mixed with a 2% w/v alginate-pectinate solution. The polymeric 
solution was then added dropwise into a 2% w/v zinc gluconate solution and left for 24 hours 
to cure. Samples were frozen at -72°C for 24 hours and lyophilised at -60°C condensation 
phase and a sublimation phase of 24 hours at 25 mmtor. 
Determination of buoyancy: Buoyancy time was determined visually, by observing 
gastrosphere characteristics in simulated gastric fluid (pH 1.2) while agitated in a shaker bath 
(SBS40 Shaking Water Bath, Stuart, New York, US) maintained at 37.5°C. A timer was used 
in order to measure the duration of buoyancy. 
Determination of bioadhesion: Bioadhesivity testing was conducted using a 
TA.XT.plus Texture Analyser (Stable Micro Systems, Surrey, UK) with a simulated 
membrane covering both the probe and platform stage. Samples were tested using an 
applied force of 2N, a contact time of 15 seconds and a trigger force of 0.04903N. The pre-
test and test speed was 0.50 mm/sec while the post-test speed was 10 mm/sec. 
 
Results 
The gastrospheres, both with and without PAA, were immediately buoyant and remained 
buoyant for greater than 72 hours. 
Bioadhesion results indicated that the addition of PAA into the alginate-pectin gastro-sphere 
formulation resulted in a more favourable bioadhesion profile. Samples containing PAA 
displayed a gradual increase in bioadhesion, showing an initial peak after 4 hours, thus 
revealing that adhesion increased over a factor of time. It was observed that samples 
containing 1% w/v PAA demonstrated optimal bioadhesivity. 
This study displayed that incorporation of PAA into alginate-pectinate gastrospheres 
successfully improved bioadhesion, without altering buoyancy. These gastrospheres may 
therefore be utilised as a gastroretentive drug delivery system for the delivery of narrow 
absorption window drugs. 
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Purpose 
To develop low density gastrospheres for improving the bioavailability of drugs absorbed in 
the ileum by increasing the gastric retention through floatation and mucoadhesion. 
 
Methods 
PLGA dissolved in 5mL dichloromethane was added to a solution of alginate, pectin, 
polyacrylic acid and model drug metformin. The blend was added drop-wise into a 1.5%w/v 
zinc gluconate solution and crosslinked for 8 hours. Gastrospheres were collected, washed, 
frozen at -72°C for 24 hours and lyophilised (-60°C; 25mmtor) for 24 hours. A rotating paddle 
apparatus in 700mL SGF (pH 1.2, 37°C) was used for drug release studies. Samples were 
analysed with UV at 241nm. For mucoadhesion analysis gastrospheres were immersed in 
SGF (pH 1.2, 37°C) and assessed with a Texture Analyser. Adhesion was determined by 
measuring the force of detachment.  
 
Results 
Zero-order release profiles were obtained that ensured a constant quantity of drug would be 
present at the absorption window over a 12 hour period. Mucoadhesion was found to be 
highly sensitive to the concentrations of polyacrylic acid used. Optimum adhesion was 
represented by the maximum force attained from 0-2 hours and over 2-12 hours. 
 
Conclusions 
The gastrospheres demonstrated a desired zero-order release as well as sufficient 
mucoadhesion in order to be retained within the gastric region. 
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Introduction 
This study evaluated three gastrosphere formulations containing varying concentrations of 
polymers in order to assess the effects of these polymers have on the physicochemical and 
physicomechanical characteristics of the drug delivery system. 
 
Methods 
An aqueous solution of metformin, alginate, pectin, PAA and PLGA was prepared and 
homogenized. The polymeric blend was injected drop-wise into 500mL of a crosslinking 
solution and allowed to crosslink over 8 hours. Crosslinked gastrospheres were collected, 
washed and frozen at -72°C for 24 hours and subsequently lyophilized at -60°C and 25mmtor 
for 24 hours. A sample of gastrospheres were immersed in 100mL simulated gastric fluid 
(SGF) and placed in an orbital shaking incubator for 12 hours. Each sample was observed at 
predetermined time intervals and observing the number of particles that were no longer 
buoyant. A sample of gastrospheres were weighed and immersed in 100mL SGF and placed 
in an orbital shaking incubator for 12 hours. The particles were dried and gravimetrically 
analyzed at predetermined time intervals. The hydrated mass was then compared to the non-
hydrated mass in order to determine the swelling (%). For bioadhesion studies samples of 
gastrospheres were immersed in SGF (pH 1.2, 37°C) for predetermined time intervals. 
Bioadhesion was measured using a TA.XTplus Texture Analyzer (Stable Microsystems, 
Surrey, UK) by measuring the force of detachment. A USP25 type 2 dissolution apparatus 
was used. Samples were immersed under a wire mesh in 700mL SGF (pH 1.2, 37°C) at 
50rpm. 5mL samples were removed, filtered and analysed under UV at predetermined time 
intervals. Equal volumes of drug-free SGF were replaced in order to maintain sink conditions. 
 
Results 
Gastrospheres were immediately buoyant, and remained buoyant for the entire 12 hour 
period which may be attributed to the highly porous structure as a result from the 
lyophilization step. Water uptake and bioadhesion of the gastrospheres are due to the highly 
hydrophilic PAA, which strongly attracted water molecules apposing the inverse effect of the 
hydrophobic PLGA. Drug release profiles revealed the significant influence of PLGA 
retarding dug release. PLGA-free formulations first-order release kinetics was achieved. 
When 1%w/v PLGA was included, an initial rapid release phase was noted at t3hours followed 
by a subsequent diffusional phase of drug release. PLGA (2%w/v) resulted in zero-order 
release kinetics due to hydrophobic nature of PLGA that resulted in the retardation of 
swelling and therefore the mechanism of drug release was erosion-dependant. 
 
Conclusions 
Results have revealed that the three gastrosphere formulations containing varying 
concentrations of polymers affected the buoyancy and the mechanism of drug release from 
the gastrospheres. Higher concentrations of PLGA resulted in more consistent drug release. 
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Introduction 
The purpose of this study was to develop an approach for the design and formulation of 
microbeads intended for local gastric drug delivery of antimicrobials for the treatment of 
Helicobacter pylori associated peptic ulcers. 
 
Methods 
An aqueous polymeric blend, comprising 1%w/v sodium alginate (SA) and 1%w/v poly(acrylic 
acid) (PAA) was prepared at 40°C for 45 minutes until homogenous. A 0.5%w/v chitosan 
(CHT) solution was prepared and added to a 2%w/v crosslinking solution of NaSO4 and 
CaCl2. The polymeric solution was added drop-wise into the crosslinking solution, while 
stirring at 700rpm under a top stirrer. The microbeads were left to cure for 4 hours and then 
collected and washed thoroughly before frozen at -72°C for 24 hours and subsequently 
lyophilised at -60°C and 25mmtor. To assess buoyancy a sample of microbeads were 
immersed in 100mL simulated gastric fluid (SGF) and placed in an orbital shaking incubator 
for 12 hours. Each sample was observed at predetermined time intervals, noting the number 
of particles that were no longer buoyant. A USP25 type 2 dissolution apparatus was used 
(Erweka DT 700, Heusenstamm, Germany). Samples were immersed under a wire mesh in 
700mL SGF (pH 1.2, 37°C) at 50rpm. 5mL samples were removed, filtered and analysed 
with UV at predetermined time intervals. Equal volumes of drug-free SGF were replaced in 
order to maintain sink conditions.  
 
Results  
The microbeads were immediately buoyant and remained buoyant for up to 12 hours. The 
buoyancy may be attributed to the highly porous structure resulting from the lyophilisation 
step. Drug release studies revealed that NaSO4 was the superior crosslinking reagent due to 
the additional retardation in drug release. An initial burst release was achieved over the first 
3 hours, followed by a controlled diffusional release phase.  
 
Conclusions  
Drug release profiles obtained from this study revealed that the gastroretentive micro-bead 
system may be suited enhancing gastric residence time and drug concentration is kept 
constant over the entire duration of treatment. 
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Introduction 
Narrow absorption window drugs posses many pitfalls which may be overcome 
through the formulation of gastroretentive drug delivery systems. 
 
Aim of study 
 To obtain an optimised formulation through the use of a Box-Behknen design, taking 
into account particular formulation parameters. 
 
Method 
A polymeric blend of alginate, pectin, PAA, metformin and PLGA was added drop 
wise into 2% calcium hydroxide. The gastrospheres cured for 30 minutes, after which they 
were collected, washed, frozen and lyophilised. 
 A randomized Box-Behnken statistical experimental design (Minitab® V15, Minitab 
Inc., PA, USA) was constructed in order to model the number of formulations required for 
optimization. The design consists of 15 statistically derived formulations.  
Drug release studies were performed using a USP XXIII type 2 dissolution test 
apparatus in 900mL SGF (pH 1.2, 37°C) at a rotation speed of 50rpm.  
Bioadhesion was determined using a TA.XT.plus Texture Analyser  with a simulated 
gastric membrane covering both the probe and platform stage. Adhesion was determined by 
comparing the force of detachment. 
 
Results 
 Three formulations achieved the appropriate zero order drug release profile, of which, 
one had the highest force of detachment. 
 
Conclusion 
An optimised formulation has been determined using the design. 
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Purpose 
A gastroretentive drug delivery system has been developed in order to deliver metformin over 
a 12 hour period. The system comprised ionically crosslinked mucoadhesive gastrospheres 
that are also buoyant within the stomach.  
Methods 
A polymeric emulsion was prepared by blending an aqueous solution of alginate, pectin, PAA 
and metformin with an organic solution of PLGA. The emulsion was then added drop-wise 
through an 18G needle into a crosslinking solution of 2% Ca(OH)2. The gastrospheres were 
allowed to cure for 30 minutes, after which they were collected, washed and frozen at -72°C 
for 24 hours. Lyophilisation was conducted on the gastrospheres at -60°C and 25mtorr for 24 
hours. A randomized Box-Behnken statistical experimental design was constructed in order to 
model the number of formulations required for optimization. The design consisted of 15 
statistically derived formulations of various polymer combinations. Drug entrapment was 
determined by immersing gastrosphere samples in 100mL PBS (pH 7.4, 37°C) and allowing 
complete drug release. Drug release studies were performed using a USP 32 type 2 dissolution 
apparatus. Samples were immersed under a wire mesh in 900mL SGF (pH 1.2, 37°C) at 
50rpm and dissolution media was removed at predetermined intervals and analysed by UV. 
Buoyancy studies were conducted by immersing the gastrospheres in simulated gastric fluid 
(SGF) and observed. Bioadhesion was determined using a TA.XTplus Texture Analyser 
(Stable Microsystems, UK) with a simulated gastric membrane covering both the probe and 
platform stage. In vivo drug release studies have been conducted on pigs which have 
surgically implanted chronic jugular catheters. The drug delivery system was administered via 
an intragastric tube while under sedation. Blood samples were extracted via the jugular 
catheter Metformin concentrations were determined by UPLC.  
Results and Discussion 
Drug release profiles were classified into three distinct types comprising zero-order release, 
burst release and first-order release. Drug entrapment ranged between 25-53%. It was 
observed that the gastrospheres displayed immediate buoyancy. The average buoyancy after 8 
hours was 98% and 96% after the full 12 hour period in SGF. Bioadhesion was primarily due 
to PAA, while the inclusion of PLGA lowered bioadhesion. The Box-Behnken design resulted 
in the optimisation of the gastrosphere formulation, achieving maximum bioadhesion as well 
as zero-order drug release. In vivo studies revealed that the gastrospheres resulted in drug 
release over a 12 hour period, the profile of which depicted a much more controlled release 
than the gold standard (Glucophage® 500). 
Conclusions 
The gastrosphere drug delivery system has proven to be retained within the stomach, resulting 
in a more desirable drug release profile, which will reduce dosing frequencies and side-effects 
and improve the bioavailability of NAW drugs such as metformin, thus improving patient 
compliance. 
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Drug Delivery 
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Purpose 
To develop a microparticulate system that will enable the controlled release of drug over an extended period of 
time employing a novel combination of chitosan and polymethacrylate polymers. 
 
Methods 
Microparticles were prepared by a W/O emulsion using a polymethacrylate (PMC) solution (organic phase) and 
chitosan (CHT) in acetic acid (aqueous phase). In addition, metformin (model drug) and Span 80 (stabilizer) was 
added. The emulsion was ultra-sonicated at 10kHz for 1 hour and thereafter 2mL of sodium tripolyphosphate 
(TPP) was added in order to ionically crosslink the CHT. The system was left to sonicate for 30 minutes and the 
resultant microparticles were filtered, washed with deionized water and allowed to air dry. Drug release data was 
obtained by immersing the microparticles in 100mL of SGF (pH 1.2; 37°C) contained in 150mL vessels and 
stored in a orbital shaking incubator (20rpm; 37°C). Samples (10mL) were removed at predetermined intervals, 
centrifuged and 3mL of the supernatant was extracted for UV analysis to ascertain metformin content. Drug-free 
SGF (3mL) was replaced into the centrifuged tube, re-dispersed and placed back into the dissolution vessel. 
Drug entrapment efficacy (DEE) was determined by placing microparticle samples in 100mL PBS (pH 
7.4, 37°C) and left overnight to ensure complete drug solubilization. Samples (10mL) were centrifuged, filtered 
and analysed using UV spectroscopy. Microscopic images were taken at 50x magnification. 
 
Results 
Digital images revealed that the microparticles varied in shape from circular to elliptical and appeared to have 
smooth surface morphologies with measured diameters of the microparticles ranging between 80-100μm. The 
cationic CHT polymer interacted with the PMC (anionic) resulting in the formation of a microparticulate 
polyelectrolyte complex. Excess CHT was crosslinked with TPP in solution that resulted in microparticles that 
were able to superiorly control the release of metformin. Drug release studies revealed that 40% of metformin 
was released after 6 hours and 80% after 12 hours with pseudo zero order drug release kinetics. DEE values 
averaged 63±1.5% (N=3). 
 
Conclusions 
A combination of chitosan and polymethacrylate polymers produced microparticles that were able to control 
drug release over a period of 12 hours with a >50% drug entrapment efficacy. 
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Abstract 
 
Electro-spinning of polymers is a unique technology which produces very fine fibres using 
electrostatic repulsive forces obtained from applying an electrical potential to a liquid. The 
resultant fibres have much smaller diameters in comparison with fibres obtained using 
different methods. Electro-spun fibres have found application in many and varied fields 
such as drug and gene delivery, tissue engineering, wound dressing, electronics, filtration 
as well as absorption and adsorption. This review will cover the various processing 
parameters which play a role in electro-spinning, including the applied voltage, solution 
flow rate, solution viscosity, solvents, solution conductivity, capillary-to-collector distances 
and the influence of surfactants. A main focus will be on the application of electro-spun 
fibres in drug delivery, where researchers have already investigated the use of these 
fibres in transdermal delivery systems, long-term implants and grafts. Different methods of 
drug incorporation will be discussed as well as numerous polymers which have been 
successfully utilised in this field, including cellulose acetate, poly(ε-caprolactone), 
poly(ethylene oxide), poly(vinyl alcohol), gelatin, poly(d,l-lactide-co-glycolide), poly(lactic 
acid), poly(l-lactic acid), polyurethane, poly(ethylene-co-vinyl acetate), poly(ethylene 
glycol), and poly(acrylic acid). 
 
Keywords: Electro-spinning, drug delivery, electrospun fibres, electrospun scaffolds, 
Parameters. 
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Abstract 
 
The effective treatment of solid tumors still continues to be a great challenge to clinicians 
despite the development of novel drugs. In order to improve the clinical efficacy of the 
existing chemotherapeutics agents, researchers have considered the possibility of local 
treatment at the site of the solid tumor. The greatest advantage of this localised delivery is 
the significantly fewer side effects experienced by the patient. In the past, the peri- or 
intra- tumoral delivery of chemotherapeutics agents was mainly based on implants that 
used to be inserted surgically into the affected region. In the recent years, in situ forming 
implants have attracted considerable interest. These are polymeric systems which are 
injected as solutions into the tumor site using commercially available syringes and 
needles. The injected solution forms an implant at the tumor site as a result of local 
environmental stimuli and hence removes the need for surgical implantation. However, 
while these implants have been shown to improve the treatment of various solid tumors, 
the ideal implant is yet to be formulated. To date, it is only a few implants that are 
biodegradable and able to deliver the chemotherapeutic agent over a prolonged period of 
time. Many of these implants also have an undesirable initial burst release effect. This 
review summarises the attempts that have so far been made in the development of 
polymeric implants for the treatment of solid tumors. 
 
Keywords: Chemotherapy, Environmental stimuli, Implant, Polymeric systems, Solid 
tumors.
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Abstract 
 
This study focussed on the formulation and evaluation of polymeric nanoparticles adopting various 
preparation approaches and attempts to explicate the mechanisms of nanoparticle formation employing 
molecular modeling and chemometrical computations. Nanoparticles were formulated using three different 
approaches such as an Emulsification/Solvent Evaporation (ESE), Emulsification/Surfactant/Solvent 
Evaporation (ESSE) and Ionic Gelification (IG) approaches. The ESE approach comprised the emulsification 
of an aqueous and organic solution, while sorbitan monooleate was added as a surfactant during the ESSE 
approach. Cation-induced crosslinking of hydrophilic alginate was employed for the IG approach. Fourier 
Transform Infrared (FT-IR) analysis was performed to elucidate any changes in the structural backbone of 
the native polymers due to nanoparticle formation. The size and morphology of nanoparticles were analysed 
by Zetasize analysis and Scanning Electron Microscopy (SEM) with photomicrographs taken at several 
magnifications. Step-wise molecular simulation models revealed the mechanisms of nanoparticle formation 
to occur via solvation, surface interactions, crosslinking/precipitation initiation and surface-volume 
minimization with sphericalization and interlaced network formation. The size distribution of the 
nanoparticles were manipulated by the surfactant introduction The addition of sorbitan monooleate prevented 
coalescence of particles, resulting in stable nano-emulsions with distinct particle morphologies and particle 
sizes and zeta potential values in the region of 200nm and -40mV, respectively. The IG approach also 
produced stable nano-emulsion with a higher yield of nanoparticles with superior size and stability control of 
confined nanoparticles. Both the ESSE and IG approaches were found to be suitable for producing stable 
nano-emulsions that may potentially be employed for the novel delivery of various drug molecules. 
 
Keywords: Polymeric nanoparticles, alginate, poly(lactide-co-glycolide), polymeric characterization, 
surfactant, crosslinking, emulsification, drug delivery 
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